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Abstract 
Adjuvants boost and shape the immune response to killed and subunit vaccines. Currently there is a 
critical need for vaccine adjuvants that induce an immune response specific for intracellular pathogens, 
or type 1 immunity. As defective viral genomes are the primary immunostimulatory molecules during 
paramyxovirus infections, we tested whether a defective viral genome-derived oligonucleotide (DDO) 
induced type 1 immune responses when used as a vaccine adjuvant. We used a model influenza vaccine 
to examine the host response to DDO-adjuvanted vaccines. Using a combination of flow cytometry, ELISA, 
qPCR, and viral challenges we showed that DDO induces all the hallmarks of a type 1 immune response in 
mice. DDO induces IgG2c antibodies, Th1 CD4+ T-cells, and effector CD8+ T-cells. In addition to inducing 
robust type 1 immunity on its own, DDO synergizes with the mixed immunity inducing adjuvant AddaVax 
(the research equivalent of MF59) to induce even stronger type 1 immune responses. As CD8+ T-cell 
responses are difficult to induce in response to killed and subunit vaccination, we next examined the 
innate immune response to DDO to discover the requirements for CD8+ T-cell activation in response to 
vaccination. We determined that DDO requires the RNA sensor TLR3 and type I IFN signaling to induce 
type 1 conventional dendritic cell (cDC1) accumulation in the draining lymph node. cDC1 accumulation 
was required for CD8+ T-cell responses. Additionally, we show DDO induces a type I IFN and inflammatory 
response that is different from the double-stranded RNA mimic poly I:C. We have shown that DDO is a 
safe and effective type 1 immunity inducing adjuvant in mice. These studies illuminate aspects of the 
innate immune response that are required to induce a type 1 immune response and identify targets for 
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Carolina B. López 
Adjuvants boost and shape the immune response to killed and subunit vaccines. 
Currently there is a critical need for vaccine adjuvants that induce an immune response 
specific for intracellular pathogens, or type 1 immunity. As defective viral genomes are 
the primary immunostimulatory molecules during paramyxovirus infections, we tested 
whether a defective viral genome-derived oligonucleotide (DDO) induced type 1 immune 
responses when used as a vaccine adjuvant. We used a model influenza vaccine to 
examine the host response to DDO-adjuvanted vaccines. Using a combination of flow 
cytometry, ELISA, qPCR, and viral challenges we showed that DDO induces all the 
hallmarks of a type 1 immune response in mice. DDO induces IgG2c antibodies, Th1 
CD4+ T-cells, and effector CD8+ T-cells. In addition to inducing robust type 1 immunity 
on its own, DDO synergizes with the mixed immunity inducing adjuvant AddaVax (the 
research equivalent of MF59) to induce even stronger type 1 immune responses. As 
CD8+ T-cell responses are difficult to induce in response to killed and subunit 
vaccination, we next examined the innate immune response to DDO to discover the 
requirements for CD8+ T-cell activation in response to vaccination. We determined that 
DDO requires the RNA sensor TLR3 and type I IFN signaling to induce type 1 
conventional dendritic cell (cDC1) accumulation in the draining lymph node. cDC1 
accumulation was required for CD8+ T-cell responses. Additionally, we show DDO 
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induces a type I IFN and inflammatory response that is different from the double-
stranded RNA mimic poly I:C. We have shown that DDO is a safe and effective type 1 
immunity inducing adjuvant in mice. These studies illuminate aspects of the innate 
immune response that are required to induce a type 1 immune response and identify 
targets for adjuvant development and improvement. 
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1.1.1 What are vaccines? 
Vaccines, along with antibiotics and improved hygiene, have led to a drastic 
increase in life expectancy in the last few decades by reducing the impact of infectious 
disease. The World Health Organization estimates that vaccines save 2-3 million lives a 
year1. Vaccines can prevent infection by dangerous and debilitating pathogens. In 
general, vaccines contain antigens, which are derived from the pathogen of interest and 
are recognized as foreign by the immune system. Antigens trick the immune system into 
thinking the body is infected by the pathogen from which they are derived and provoke 
an immune response against the pathogen. Once an effective immune response is 
generated against a vaccinated antigen, future infection by the targeted pathogen can be 
recognized and neutralized by the immune system, leading to disease prevention.  
While there has been great progress in the development of vaccines to prevent a 
wide array of diseases, recent events, such as the COVID-19 pandemic, underscore the 
constant need for new and improved vaccines. Additionally, certain populations such as 
young infants and older adults typically respond poorly to vaccination2,3, resulting in 
subpar protection. Not only are new vaccines needed to target emerging pathogens, but 
new vaccination strategies are needed to protect all individuals.  
1.1.2 Types of vaccines 
Vaccines can be divided into categories based on the type of antigens used and 
how they are introduced to the host. These different subgroups of vaccines work through 
distinct mechanisms to induce immune responses. There are two main vaccine subtypes 
that are licensed for use in humans, but other vaccination types are having increased 
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success in clinical trials. Attenuated vaccines use live, but weakened, pathogens to 
induce immune responses, while killed and subunit vaccines rely on inert antigens to 
generate immunity. Both of these categories of vaccines have been successful in 
preventing disease, but also have drawbacks.  
The first vaccines produced were live-attenuated vaccines. Live-attenuated 
vaccines are created by using related pathogens that do not cause disease in the target 
host or by growing the pathogen in conditions that reduce its virulence in the host. The 
smallpox vaccine was the first successful vaccine and was originally used in 1796 by 
Edward Jenner. Jenner used cowpox virus, a cousin of the virus that caused smallpox, 
to vaccinate against smallpox4. The word vaccine comes from “vacca” the Latin word for 
cow. Attenuated pathogens replicate and mimic an infection with a virulent pathogen and 
trick the immune system into developing a robust, protective immune response. Current 
examples of live attenuated vaccines include the measles, mumps, and rubella (MMR) 
vaccine, oral polio vaccine, varicella vaccine, rotavirus vaccine, yellow fever vaccine, 
nasal spray influenza vaccine, oral cholera vaccine, and oral typhoid vaccine5.  
While attenuated vaccines induce robust immune responses, there are several 
important issues with their use. Attenuated vaccines use live microbes and therefore 
have the potential to revert to virulence or cause disease. Oral polio vaccination is a 
classic example of vaccine-induced disease and is currently the cause of multiple polio 
outbreaks throughout the world6. Additionally, live-attenuated vaccines have the potential 
to cause disease in the growing population of immunocompromised individuals. 
Attenuated vaccines are safe for most people, but it is important to develop vaccines that 
are safe for all.  
4 
 
The other main vaccine category uses either killed pathogens or 
immunodominant pathogen subunits. These non-replicative vaccines can be further 
divided into subcategories including recombinant protein vaccines that provide the 
minimal antigen required for protective immunity. For example, polysaccharide vaccines 
are composed of the complex sugar covering of many bacteria, while toxoid vaccines 
contain an inactivated form of the bacterial toxin responsible for causing disease. Killed 
virus vaccines contain either full or partial inactivated virus. Some examples of subunit 
and killed vaccines are hepatitis B vaccine, human papilloma virus vaccine, zoster 
vaccine, meningococcal vaccine, diphtheria, tetanus, and pertussis vaccine, hepatitis A 
vaccine, some influenza vaccines, Japanese encephalitis virus vaccine, polio vaccine, 
rabies virus vaccine, Haemophilus influenzae type b vaccine, and pneumococcal 
vaccines5. 
Killed and subunit vaccines contain the antigens required to elicit protective 
immune responses, but without a live pathogen or replication, they lack a critical set of 
danger signals that indicate an active infection7. Because of the loss of replication and 
infection, these vaccines may struggle to induce a robust protective immune response to 
inert antigens. In contrast to attenuated vaccines, subunit and killed vaccines are unable 
to revert to virulence as they do not contain intact pathogens and do not cause disease 
in immunocompromised individuals. 
Vector based vaccines work similarly to live attenuated vaccines and use a live 
virus to deliver antigen. Vector viruses contain a gene or genes for antigens specific to 
the target pathogen. In contrast to live-attenuated vaccines, vector-based vaccines 
typically use a non-pathogenic virus, such as adeno virus, to act as a vector8. Upon 
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vaccination, the vector virus infects the host and produces antigen of the targeted 
pathogen. A vectored rabies vaccine for wildlife was the first widely used vectored 
vaccine with great success9. Currently, there are no licensed vector-based vaccines for 
humans in the US, however many vector-based vaccines are in clinical trials.  
Great strides have been made in the field of nucleic acid vaccination. Nucleic 
acid vaccination uses mRNA or DNA to code for antigen. Upon vaccination, the injected 
tissue produces antigen and an immune response is generated10,11. Nucleic acid 
vaccines are safe for immunocompromised individuals and, because they do not contain 
a pathogen, they are not able to cause disease. Nucleic acid vaccines function 
differently than traditional vaccination methods and therefore will not be further 
discussed.  
1.1.3 What are vaccine adjuvants? 
Adjuvants are added to vaccines containing inert antigens to provided danger 
signals and stimulate the host response to immunization and are critical for many killed 
or subunit vaccines to produce robust immune responses12. The first adjuvants used in 
vaccines were chosen using trial and error approaches13. These pioneer adjuvants 
boosted immune responses, but their immunostimulatory properties were not well 
understood13. Recent studies have begun to shed light on their mechanisms of action7. 
Adjuvants reduce the amount of antigen and number of doses required to achieve 
protective immune responses, factors that are important for mass vaccination, especially 
in times of pandemics or antigen shortages. While adjuvants are critical for increasing 
the magnitude of the adaptive immune response, they also skew the type of adaptive 
immune response, shaping the response for specific types of pathogens14. Therefore, it 
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is critical to use an adjuvant that induces an immune response effective against the 
vaccine-targeted pathogen.  
The first adjuvant, aluminum salts (alum), was introduced in the 1920s15. After 
alum, there were few new adjuvants until the past decade, where there has been an 
exponential increase in new vaccine adjuvants. New adjuvants include emulsions, 
particulates, and pathogen mimics13. While there has been a lot of progress in vaccine 
development, the field still lacks adjuvants that skew the immune response towards 
those required for clearance of intracellular pathogens.  Viruses and other small 
intracellular pathogens replicate inside of cells and require specialized immune 
responses to detect infected cells without directly interacting with the pathogen. A 
deeper discussion on the immune response to adjuvanted vaccines will occur in section 
1.2.4 after adaptive immunity is introduced.  
Studying adjuvants not only leads to be better vaccines, but also aids in 
understanding immune responses. During infections, there are many processes 
occurring simultaneously that influence the immune response including antigen 
production, pathogen replication, and pathogen-specific mechanisms to block immune 
responses. Adjuvants provide a simplified danger signal that allow us to gain deeper 
insight into the role specific pathways play in generating immune responses in the 
absence of the confounding factors of infection. 
1.2 The adaptive immune response 
1.2.1 What is an adaptive immune response? 
Adaptive immunity is a trained response to a specific pathogen that typically 
prevents subsequent infections and the goal of vaccinations is to induce adaptive 
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immune responses and prevent disease. Adaptive immune responses are comprised of 
specialized cells that recognize and respond to their cognate antigen. Upon detecting an 
infection, the innate immune response (described in detail in section1.3) releases 
cytokines that instruct adaptive immune cells to take on specific characteristics. These 
different characteristics are used to subdivide immune responses to into different types.  
Adaptive immune responses are composed of two arms, cellular and humoral 
responses. Cellular responses include T-cells which can be further broken down into 
CD8+ T-cells and CD4+ T-cells. T-cells indirectly recognize fragments of antigens 
through a process called antigen presentation. Activation of naïve T-cell relies on a 
specialized set of cells called antigen presentation cells (APCs) that use co-stimulatory 
molecules and cytokine secretion to shape the T-cell response. CD8+ T-cells, also called 
cytotoxic T lymphocytes (CTLs), recognize and kill infected cells. CD4+ T-cells provide 
cytokines that instruct cells how to respond to an infection or stimulus. CD4+ T-cells are 
characterized by the cytokines they produce and the transcription factors they express. 
Many adaptive immune responses are referred to by their CD4+ T-cell phenotype.  
The humoral response is composed of B cells and the antibodies they produce. 
Antibodies bind to specific regions of the pathogen they target, called epitopes, using 
their variable region. Antibody binding to pathogens can prevent infection, a process 
called neutralization. Opposite to the variable region is the constant region which 
determines the antibody isotype. Isotypes have different functions during immune 
responses16. Cells expressing Fc receptors bind to the isotype-specific constant region 
of the antibody and this binding can lead to the activation of immune cells, instructing 
them to carry out their effector functions. Other antibody isotypes bind inhibitory Fc 
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receptors and prevent immune cell activation. The signals B cells receive during their 
activation lead to the secretion of different antibody isotypes. A subset of CD4+ T-cells, 
T follicular helper cells (Tfhs), interact with B cells and instruct isotype switching based 
on the cytokines produced during Tfh-B cell communication. Antibody responses that 
require T-cell interaction with B cells are referred to as T-cell-dependent responses. In 
mice, IgG1 and IgG2a/c are T-cell dependent isotypes17. Other antibody isotypes, such 
as IgG2b in mice, do not require B cell interactions with Tfhs and are called T-cell-
independent responses17.  
The T-cell response and the antibodies produced allow for immune responses to 
categorized into subtypes. The most studied types of immunity are type 1 and type 2 
immunity. These responses represent opposite ends of the spectrum of immunity. Type 
1 immune responses are critical for the clearance of intracellular pathogens such as 
viruses and intracellular parasites. Type 2 immunity is critical for the clearance of large 
extracellular parasites and is a driver of allergic inflammation. While the type 1/ type 2 
immunity dichotomy is best characterized, other forms of adaptive immune responses 
are recognized as key factors for the control of pathogens and tissue homeostasis.  
Th17 immunity, sometimes referred to as type 3 immunity, has gained attention 
as an important subdivision of adaptive immunity. Th17 immunity is classically defined 
by the presence of a specific cytokine, IL-17, producing CD4+ T-cells (Th17 cells), first 
described in 200518–20. Like all adaptive immune responses, Th17 immunity requires a 
careful balance to protect from infection without causing disease21. Th17 immunity is 
important for the clearance or control of extracellular bacteria and fungi such as 
Streptococcus pneumoniae22, Klebsiella pneumoniae23, Citrobacter rodentium24, 
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Candida albicans25 and others. Overactivation of Th17 immunity has been associated 
with pathology during Bordetella pertussis infections26 and multiple inflammatory 
diseases including multiple sclerosis27, inflammatory bowel disease28, rheumatoid 
arthritis29.  
In addition to immune responses aimed at pathogen clearance, regulatory 
immune responses have evolved to prevent autoimmunity and promote balanced 
immune responses. A subset of CD4+ T-cells, regulatory T-cells (Tregs), are particularly 
important for preventing recognition of self. Conventional Tregs form in the thymus and 
recognize self-antigen30. Additionally, non-thymus derived Tregs develop in the 
periphery in the presence of TGF-β and IL-231. Tregs aid in limiting autoimmune 
responses through acting as a sink for IL-2, a cytokine important for T-cell activation and 
maintenance, and by limiting costimulatory molecule expression by antigen presenting 
cells32. Strategies to limit Tregs are of interest to the field of cancer immunology33, 
whereas Treg expansion is being examined for control of autoimmune disease32.  
No adaptive immune response can be completely characterized by a single 
subtype of immunity. Adaptive immunity is a diverse spectrum of cellular and humoral 
components and protection from disease requires a careful balance of appropriate 
immune responses. Type 1 and type 2 immunity have very clearly defined roles during 
vaccination and will be discussed in detail in the following sections . Figure 1.1 provides 






Figure 1.1 Outline of type 1 and type 2 immune responses. Many factors lead to the 
induction of type 1 and type 2 immunity, this figure summarizes some of the key factors 
involved. Type 1 immunity is induced in response to intracellular pathogens, typically the 
pathogen or pathogen components are directly sensed to lead to cytokine release by the 
infected tissue. In contrast, type 2 immunity is typically induced in response to tissue 
damage due to extracellular pathogens. Both type 1 and type 2 immunity begin with the 
recruitment and activation of many innate cells, these cells secrete many cytokines that 
shape the adaptive immune response. Examples of cytokines secreted by dendritic cells 
to activate naïve T-cells are provided. The adaptive immune response is composed of T-
cells and antibodies. These cytokines and antibodies further interact with innate immune 
cells to potentiate the adaptive immune response. This figure was created in 
BioRender.com. 
1.2.2 Type 1 immunity 
Type 1 immune responses are important for the clearance of intracellular 
pathogens, such as viruses. Intracellular pathogens enter cells and replicate; therefore, 
the immune response must be able to detect infected cells without directly interacting 
with the pathogen they target. Developing robust type 1 immunity inducing vaccine 
adjuvants is critical for killed or subunit vaccination against intracellular pathogens.  
The cellular arm of the type 1 immune response is composed of type 1 helper 
CD4+ T-cells (Th1 cells) and CD8+ T-cells. Th1 cells secrete cytokines that shape and 
potentiate the immune response and are required for the control of various infections 
such as leishmania34,35. Th1 cells are activated in response to recognizing peptide 
presented in major histocompatibility class II (MHC-II). MHC-II presentation occurs in a 
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subset of specialized antigen presenting cells. Th1 cells are differentiated upon type I 
interferon (IFN) or IL-12 signaling and are characterized by the expression of the 
transcription factor T-bet and the secretion of cytokines such as IFNɣ and TNFα36. IFNɣ 
is particularly important as it drives the further production of IFNɣ and leads to the 
activation of innate immunity cells. Cells such as macrophages are instructed to up 
regulate components of their phagocytic pathway leading to increased killing of 
phagocytosed pathogens37. Natural killer cells (NK) cells respond to and produce IFNɣ. 
NK cells can kill infected cells and important drivers of non-self recognition38.  
CD8+ T-cells are unique to type 1 immune responses and are important for the 
recognition and clearance of infected cells. Upon recognition of infected cells, CD8+ T-
cell can secrete granzymes and perforin to kill infected cells39. They can also act by 
secreting IFNɣ. CD8+ T-cells are generated during infections and live vaccinations but 
are difficult to generate in response to killed and subunit vaccines. CD8+ T-cells are 
activated in response to MHC-I-peptide presentation. All cells can present antigen in 
MHC-I, however conventional MHC-I presentation requires the cell to be infected with a 
pathogen. During vaccination, inert antigens are not easily presented on MHC-I and 
additional signaling, typically adjuvant driven, is required for cells to cross-present inert 
antigen in MHC-I40–42. Cross-presentation will be discussed further below.  
The humoral arm of the type 1 immune response is composed of different IgG 
antibody subtypes. In mice, the IgG subtypes IgG2b and IgG2a/c (IgG2a is found in 
Balb/c mice, IgG2c is found in C57Bl/6 mice) dominate the antibody response. IgG2b 
isotype switching is T-cell independent and driven by TGF-β. IgG2a/c class switching is 
T-cell dependent and driven by type I IFN and IFNɣ signaling17,43. IgG2c binds tightly to 
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activating Fc receptors and is important for antibody-dependent cellular cytotoxicity 
(ADCC) by innate cells such as NK cells17. 
The type 1 immune response evolved to clear intracellular infections without 
directly interacting with the pathogen it targets. This coordinated attack of hidden 
pathogens has been difficult to replicate during vaccinations with inert antigens. Because 
of this, adjuvants are an important tool to induce this type of immune response during 
vaccination. 
1.2.3 Type 2 immunity 
Type 2 immune responses are critical for the clearance of large extracellular 
pathogens, such as parasites. Additionally, type 2 immunity is the hallmark of allergic 
responses. Type 2 immune responses are triggered by signals associated with tissue 
damage caused by large extracellular parasites. The alarmin cytokines IL-33, IL-25, and 
Thymic Stromal Lymphopoietin (TSLP) are released from non-hematopoietic cells at the 
site of infection or damage and act as key drivers of type 2 immunity induction44. It is 
also increasingly apparent that type 2 innate lymphoid cells (ILC2s) are important 
initiators and drivers of type 2 immunity.  
The cellular response during type 2 immune responses is largely characterized 
by Type 2 helper CD4+ T-cells (Th2 cells). The differentiation of Th2 cells was 
traditionally thought to be driven by IL-4 secretion by antigen presenting cells. However, 
ILC2-APC interactions are now recognized as key drivers of IL-4 secretion and Th2 
skewing45. Th2 cells are characterized by the expression of the transcription factor 
GATA3 and the secretion of one of more of the following cytokines: IL-5, IL-4, IL-13, and 
IL-1044. These cytokines are important for shaping the type 2 immune response.  
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The humoral arm of the type 2 immune response is composed of B cells and 
antibodies. IgE is a hallmark of allergic reactions and isotype switching to IgE is driven 
by IL-5. IgE binds to mast cells and basophils and leads to the release of histamines46. 
In addition to IgE, some IgG antibodies are secreted during type 2 immune responses. In 
mice, IgG1 is closely associated with type 2 immune responses and is commonly 
induced upon vaccination with alum-adjuvanted vaccines47. IgG1 isotype switching 
requires T-cell help to B cells and is driven by IL-4 signaling. IgG1 does not fix 
compliment and only binds inhibitory Fc receptors; therefore, IgG1 does not have 
effector capabilities outside of binding and neutralizing pathogens17.  
In addition to antibody and T-cell responses, other cells such as eosinophils, 
basophils, mast cells, and innate lymphoid cells aid in the induction and potentiation of a 
type 2 immune response. In many instances, type 2 immunity is described as employing 
a “weep and sweep” approach alluding to the increased mucus production and muscle 
contractions geared at expelling pathogens46.  
Type 2 immune responses are important for the clearance of many pathogens. 
However, type 2 dominated immune responses to some pathogens, such as respiratory 
viruses, cause more severe disease. Type 2 immunity is insufficient for clearance of 
respiratory viruses and leads to increased mucus production and thickening of the 
airways which results in increased difficulty breathing. In studies examining rhinovirus 
(RV) infections in premature infants and asthmatic children, patients with higher Th2 
associated cytokines had worsened asthmatic disease scores, increased immune cell 
counts, or increased lower respiratory tract disease 48–50. Similar evidence of enhanced 
disease upon type 2 immunity induction in response to respiratory syncytial virus (RSV) 
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has also been observed51. Th2 skewing is not only problematic during infection settings 
but can also lead to enhanced disease upon challenge after vaccination against 
respiratory viruses.  
1.2.4 Adaptive immune responses to adjuvanted vaccines 
Alum, the oldest and most widely used vaccine adjuvant, induces type 2 immune 
responses upon vaccination. Alum-containing vaccines can induce strong neutralizing 
antibody responses, which is effective in controlling some pathogens. However, type 2 
immunity can be detrimental to the host in response to some pathogens. Early studies 
with RSV vaccination resulted in poor responses to viral infection in human infants, 
further investigation revealed type 2 immunity as a driver of increased morbidity in a 
mouse model52. Similar results were observed with early SARS-CoV-1 vaccination 
studies that included the type 2 immunity inducing adjuvant alum53.  Therefore, 
adjuvants that induce type 2 immunity should not be used in all vaccines.  
Over the years, more adjuvants have made it into the clinic and have been 
licensed. Currently licensed adjuvants in the US include the oil-in-water emulsion 
adjuvant MF59, which induces a mixed type 1/type 2 immune response consisting of a 
robust antibody repertoire and CD4+ T-cells that produce Th1 and Th2 cytokines54,55. 
Other adjuvants include the adjuvant system AS01, an emulsion consisting of QS-21, 
derived from the bark of a tree, and 3-O-desacyl-4′-monophosphoryl lipid A (MPL), a 
lipopolysaccharide derivative from Salmonella Minnesota56. AS01 is capable of inducing 
IFN ɣ-dependent Th1 responses and has shown modest CD8+ T-cell activation56,57. 
Additionally, a CpG, nucleic acid-based adjuvant, is currently in use in an adult hepatitis 
B vaccine and induces robust antibody responses58. More adjuvants are currently under 
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investigation, many of these mimic pathogens and infections and will be discussed 
further in the next section.  
While more adjuvants have made it to the clinic, producing an adjuvant that 
induces type 1 immunity, including robust CD8+ T-cell responses, has remained elusive. 
The issue remains that it is unclear what is required of a vaccine adjuvant to induce a 
type 1 immune response. Responses to vaccination, while similar to infection, are 
distinct from responses to live pathogens. Adjuvants are simpler signals than infections 
and therefore induce specific, rather than broad, immune responses. Early adjuvant 
development focused solely on the adaptive immune response to adjuvanted vaccines, 
whereas adjuvants play their part before the adaptive immune response is generated. To 
create adjuvants that induce robust type 1 immunity, it must first be understood what 
early steps are required and what innate immune responses to adjuvants lead to type 1 
adaptive immunity.  
1.3 The induction of adaptive immune responses 
1.3.1 What is innate immunity? 
For adaptive immunity to occur, the pathogen must first be detected by cells that 
recognize patterns common to pathogens or tissue damage. Cells at the site of infection 
or vaccination act as sentinels. Cells such as epithelial cells and other cells at barrier 
sites are equipped to detect invading pathogens and release proteins called cytokines 
and chemokines. The type of stimulus or danger signal detected instructs the type of 
cytokines released. Cytokines and chemokines are the primary language of the immune 
system. Cytokines instruct other cells to prepare for infection, activate immune cells, and 
instruct the adaptive immune response. Chemokines are proteins that attract immune 
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cells to the site of infection or vaccination and allow for their homing to the lymphoid 
tissue.  
Innate immune cells can directly sense invading pathogens or are drawn to the 
infection site by the chemokines released by tissue resident cells.  Innate immune cells 
are diverse with broad functions and include monocytes, macrophages, ILCs, natural 
killer cells, neutrophils, dendritic cells (DCs) and others. A subset of innate immune cells 
called antigen presenting cells travel from the site of infection to the draining lymph node 
and translate innate signals to instruct a tailored adaptive immune response.  
Innate immune cells are one of the first lines of defense against invading 
pathogens and each cell type fills a different immunological niche. Monocytes circulate in 
the vasculature and are recruited to the site on infection or inflammation where they can 
differentiate into macrophages or DCs59. Macrophages are found in most mammalian 
tissues where they patrol for damage or invaders. Their main job is to phagocytose 
apoptotic cells or pathogens. Macrophages aid in tissue repair and pathogen defense 
and may act as antigen presenting cells resulting in T-cell activation60. DCs are critical 
for the activation of naïve T-cells in many immune responses, these cells are important 
translators of innate immunity into adaptive immune responses61. NK cells are key cells 
in antiviral and antitumor responses. NK cells are important sources of IFNɣ during 
infections and kill cells based on MHC-I expression loss or through ADCC, thereby 
acting as the innate equivalent of CD8+ T-cells38. ILCs similarly reflect CD4+ T-cells and 
act as their innate counterpart. ILCs are subdivided in to ILC1, ILC2, and ILC3 whose 
cytokine profiles mirror Th1, Th2, and Th17 cells, respectively. ILCs provide early 
cytokines that aid in shaping the adaptive immune response62. As new tools are being 
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developed, the roles and contributions of ILCs during immune responses are becoming 
increasingly clear. Short lived neutrophils act as a first line of defense against invading 
pathogens through the use of antimicrobial granules, phagocytosis and reactive oxygen 
species, and neutrophil extracellular traps (NETS)63. Together, these innate cells form 
the foundation of an immune response.  
1.3.2 Pathogen associated molecular patterns and pattern recognition receptors 
Infections are first detected through a series of sensors called pattern recognition 
receptors (PRRs). PRRs are a diverse set of proteins that recognize pathogen 
associated molecular patterns (PAMPs). PAMPs are conserved motifs and patterns that 
constitute as the building blocks of pathogens. PRR recognize patterns that are absent 
from the host or are found in the wrong intracellular compartment, such as DNA in 
endosomes. PRRs recognize broad categories of pathogens and are not specific to the 
exact pathogen they target. Some PAMPs include structural components of bacteria 
such as lipopolysaccharide and flagellin, while others include components of viral 
infections such as nucleic acid that looks different from the host (uncapped or doubled-
stranded RNA) or is in the wrong location (endosomes). PRR expression varies between 
species and the following information pertains to mice unless specified otherwise.  
PRRs are subdivided into families. Toll-like receptors (TLRs) were the first 
described PRRs64. TLRs are membrane bound sensors that can be found both in the 
plasma membrane or in the endocytic compartment. In humans and mice there are 10 
and 12 TLRs, respectively65. In general, TLRs located on the plasma membrane 
recognize pathogen membrane components such as lipids, lipoproteins, and proteins. 
TLRs in the endocytic compartment recognize nucleic acids. TLR expression is limited to 
19 
 
specific subsets of cells such as epithelial cells, fibroblasts, and immune cells at 
baseline. Nucleic acids are common PAMPs during RNA virus infections. TLR3, located 
the endocytic compartment of innate immune cells, is expressed in all innate immune 
cells except pDCs and neutrophils and is highly expressed in conventional DCs type 1 
(cDC1)66–68. TLR3 recognizes dsRNA typical of viral infections69 and stem loops in 
ssRNA70. TLR3 signals through the adaptor TIR-domain-containing adapter-inducing 
interferon-β (TRIF) to lead to the expression of the type I IFN IFNβ and inflammatory 
cytokines71,72.  
TLR7 and TLR8 are also located in the endosome of immune cells. TLR7 is 
highly expressed in pDCs and B cells and TLR8 is more commonly expressed in 
lymphocytes and cDCs. Both TLR7 and TLR8 recognize ssRNA73 and signal through the 
adaptor Myeloid differentiation primary response 88 (MyD88) to induce type I IFN and 
cytokine expression74. TLR7/8 originally were found to recognize small molecules such 
as imidazoquinoline derivatives as well as polyU RNA and short interfering RNA75,76. 
Because nucleic acid sensing TLRs are located in the endocytic compartment of 
phagocytic cells, antigen and PAMPs enter cells through the same pathway, allowing for 
a coordinated response.  
The RIG-I-like receptors (RLRs) are a second family of RNA sensors that are 
important initiators of antiviral responses. There are 3 known RLRs, retinoic acid-
inducible gene-I (RIG-I), melanoma differentiation-associated protein 5 (MDA5), and 
laboratory of genetics and physiology 2 (LGP2). RLRs can be expressed in the cytosol 
of all nucleated mammalian cells66. RIG-I and MDA5 signal through the adaptor 
Mitochondrial Antiviral-Signaling protein (MAVS) to induce a type I IFN response77–80. 
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LGP2 is thought to have a regulatory role, as it does not contain a signaling domain and 
does not interact with MAVS81. RIG-I recognizes 5’ppp and 5’pp on the ends of 
structured ssRNA or short dsRNA aiding in its designation of non-self RNA82,83. MDA5 
recognizes longer dsRNA structures than RIG-I84. RIG-I and MDA5 are important 
sensors of viral infections.  
A variety of other nucleic acid sensors exist that play an import role in host 
defense against pathogens. A third sensing pathway is the cyclic GMP–AMP synthase 
(cGAS)- signaling effector stimulator of interferon genes (STING) pathway. cGAS 
directly recognizes cytosolic DNA, not typically found in healthy cells, and synthesizes 
cyclic GMP–AMP (cGAMP), which acts as a second messenger to activate STING85,86. 
ER stress, viral liposomes, and cyclic dinucleotides are also capable of activating 
STING87–89. Absent in melanoma 2 (AIM2) forms the AIM inflammasome upon 
intracellular DNA recognition90–92. Polymerase III can synthesize RNA from cytosolic 
DNA, the resulting RNA can then interact with RLRs and lead to downstream 
signaling93,94. A cytosolic component of IFN-γ inducible protein 16 (IFI16) recognizes 
DNA and leads to STING-pathway signaling95. RNA sensing may lead to the activation 
of NLRP3-inflammasome96, Nucleotide Binding Oligomerization Domain Containing 2 
(NOD2)97, and a growing number DExD/H-box helicases proteins66 and results in the 
production or release of type I IFN, inflammatory cytokines, or chemokines66. The vast 
number of pathways that have evolved to detect abhorrent nucleic acids in the cytosol 
illustrate their importance in pathogen recognition and sensing.  
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1.3.3 PAMPs as adjuvants 
PAMPs and PAMP mimics are widely investigated for use immunostimulants and 
adjuvants. The most widely studied synthetic nucleic acid immunostimulant is 
Polyinosinic:polycytidylic acid (poly I:C). Poly I:C is a heterogenous dsRNA mimic and 
was once thought to be the answer for a type 1 immunity inducing adjuvant. Poly I:C is 
sensed through TLR3 in vivo69 and induces CD8+ T-cell activation when used as a 
vaccine adjuvant98. Poly I:C has served as a great tool to begin to unravel innate 
immunity induction. Poly I:C showed great success in mice, however due to systemic 
type I IFN responses and the resulting adverse events post-vaccination, poly I:C was not 
suitable to human use99. While poly I:C has been very useful to understand innate 
immune activation, hurdles in vaccine safety and lack of homology to natural viral 
PAMPs limit its use in mechanistic studies.  
The gram-negative bacteria cell membrane component lipopolysaccharide (LPS) 
was first tested as an adjuvant in 19557. LPS has robust immunostimulatory properties 
but its endotoxic effects make it an unsuitable adjuvant100. A detoxified LPS derivative, 
MPL, is currently a part of the adjuvants AS04 and ASO114. MPL is a TLR4 agonist that 
skews a Th1 dominated immune response in the licensed subunit Zoster vaccine57,101.  
Another PAMP adjuvant in licensed vaccines is cytidine-phosphate-guanosine 
oligodeoxynucleotide (CpG-ODN). CpG-ODN is sensed through endosomal TLR9 and is 
able to induce robust humoral immune responses in high-risk groups upon hepatitis B 
vaccination58. While the licensed CpG-ODN induces type 1 immunity associated 
antibody responses, CpG-ODN’s ability to induce robust CD8+ T-cell response in 
humans remains to be fully examined.  
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Other PRR agonists have been investigated or are currently being investigated 
as adjuvants. Examples include TLR7/8 agonists such as R848, which was poorly 
tolerated in humans due to systemic cytokine responses after injection102,103. Another 
class of immunostimulants, cyclic dinucleotides, activate the STING pathway and have 
been explored as type 1 immunity inducing adjuvants but have received less attention 
than TLR agonists104. New PAMPs and PRRs are being defined, leading to a greater 
quantity of experimental adjuvants and enhancing our understanding of immune 
responses and the requirements for effective adjuvants.  
The successes and failures of PRR agonist adjuvants have greatly hinged on the 
ability of the agonist to induce robust immune responses without causing systemic 
adverse events or toxicity.  
1.3.4 Key Innate Cytokines 
Cytokines are important messengers of the immune system. The cytokines 
released early during an immune response shape the subsequent events that lead to an 
adaptive response. Upon stimulation, such as sensing an infection through PRR 
engagement, cytokines are released that communicate with neighboring cells as well as 
recruited immune cells. Cytokines are a primary form of communication between cells 
during each stage of an immune response.  
Type I IFNs are a family of pleotropic cytokines that are released early during 
infections but can shape the immune response at every step, from the site of infection to 
isotype switching by B cells. Type I IFN production is be induced through PAMP sensing 
by PRRs such as TLRs, RLRs, and STING105. Type I IFN is broadly thought of as an 
antiviral cytokine and can be expressed in almost all cells. IFNβ acts as a primary type I 
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IFN, whereas other type I IFNs, such as most IFNαs, may be produced after initial 
sensing of PAMPs105. pDC are specialized cells that release high volumes of IFNα upon 
viral sensing106. Upon binding to IFN receptors, type I IFN induces an antiviral state in 
cells through the induction of interferon stimulated genes (ISGs) that limit virus 
replication and spread107.  
Type I IFN not only acts as an antiviral cytokine but also shapes DC activation 
and maturation. Type I IFN induces DC maturation as evidenced by increased 
expression of MHC and co-stimulatory molecules and increased expression of 
chemokine receptors necessary for lymph node homing108–110. Type I IFN is shown to be 
required for cross-presentation by cDC1s in response synthetic PAMPs and 
infection111,112. Cross-presentation is critical for CD8+ T-cell activation during vaccination 
with subunit or killed vaccines, as it facilitates the presentation of phagocytosed antigen 
on MHC-I. Interestingly, type I IFN negatively regulates the production of IL-12 another 
type 1 immunity driver113. Additionally, autocrine type I IFN signaling in DCs leads to the 
expression of IL-27114, a cytokine important for CD8+ T-cell responses to 
vaccination115,116.  
In addition to acting directly on DCs, type I IFN directly acts on adaptive immune 
cells. Type I IFN acts as signal 3 and in concert with peptide-MHC and costimulatory 
molecules activate CD8+ T-cells117,118 and aids in the formation of memory CD8+ T-cells 
after viral challenge119. The importance of timing of IFN reaching the lymph node is 
demonstrated during mRNA vaccinations120: if naïve T-cells are stimulated by type I IFN 
before antigen, they are not activated and are unable to proliferate121. In contrast, if T-
cells are exposed to antigen prior to type I IFN, IFN can act as signal 3 and induce 
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activation and proliferation117. The role of type I IFN in CD4+ T-cell activation and 
phenotype skewing is conflicting. While type I IFN induces T-bet expression in CD8+ T-
cells, the ability to act as signal 3 in CD4+ T-cell differs between species. Type I IFN can 
act as a signal 3 for human but not mouse CD4+ T-cells122,123, however type I IFN 
signaling in murine DCs is important for Th1 skewing in the absence of IL-12124. Finally, 
type I IFN shapes the humoral response to infections and vaccinations. Direct sensing of 
PAMPs by B cells induces type I IFN production and during Tfh-B cell communications, 
type I IFN educates both the Tfh and B cell resulting in IgG2a/c isotype switching in 
mice125–127. 
Other cytokines released at the site of infection or in the lymph node are 
important for adaptive immunity instruction. In addition to type I IFN, PRR engagement 
leads to the production of inflammatory cytokines such as tumor necrosis factor α 
(TNFα), IL-6, and IL-1 family cytokines. TNFα activates macrophages and can lead to 
increased inflammatory cytokine production and can induce apoptosis, survival, or 
proliferation depending on the receptors expressed by cells and signals received from 
other cytokines128. IL-6 is important for stimulating neutrophil expansion and recruitment 
to the site of infection or inflammation. IL-6 also induces the secretion of chemokines 
CXCL5, CXCL6, CCL2 and CCL8 that attract immune cells such as neutrophils and 
monocytes to the cite of infection. In addition to aiding in the innate immune response, 
IL-6 aids in shaping the adaptive response. IL-6 is important for promoting Tfh skewing 
and induces T-cells to produce IL-17129.  
The IL-1 family of cytokines are a diverse group of cytokines that have both 
innate and adaptive immunity roles. The IL-1 family of cytokines includes IL-1α, IL-1β, 
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IL-18, and others. These cytokines are translated as inactive precursors130,131. IL-1 is 
released upon cell death and induces chemokine expression and immune cell infiltration. 
IL-1β expression is induced upon PRR engagement or through IL-1 receptor signaling. 
IL-1 stimulates the expansion of T-cells after they encounter antigen132. Additionally, IL-
18 leads to IFNɣ production by NK cells and T-cells. IL-18 is also important for 
sustaining CD4+ and CD8+ T-cell activation130,131.  
As stated above, IL-27 expression is driven by PAMP sensing and type I IFN 
signaling114. IL-27 is an IL-12 family cytokine with complex immunomodulatory 
properties. IL-27 was first thought to promote Th1 responses due to early studies where 
it activated CD4+ T-cells, induced T-bet expression,  induced IFNɣ expression by NK 
cells, and skewed CD4+ T-cells away from Th17 polarization133. However, later studies 
illustrated its role in limiting T-cell responses and immunopathology by promoting IL-10 
production by T-cells134–137, underscoring the concept that many cytokines are not strictly 
pro- or anti-inflammatory. Instead, the sum of the cytokines produced are important 
drivers of inflammation. More recently, work from the Kedl lab has uncovered IL-27 as a 
key cytokine produced by cDC1s upon subunit vaccination to lead to a memory CD8+ T-
cell responses115,116,138.  
Finally, IL-12 is another important driver of type 1 immune responses. IL-12 
expression by APCs leads to the skewing of CD4+ T-cells to a Th1 phenotype including 
the production of IFNɣ and leads to the activation of CD8+ T-cells139. IL-12 expression is 
driven by PRR engagement, however type I IFN production typical of viral infections 
restricts IL-12 production by APCs140.  
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A milieu of cytokines is produced during innate immune responses that work 
together to create the innate immune environment. However, innate cytokines are rarely 
only involved in the innate immune response. These cytokines are critical for instructing 
the characteristics needed for appropriate adaptive immunity. Understanding the early 
cytokines produced during immune responses is critical to understand how we can 
create targeted adaptive immune responses.  
1.3.5 Antigen presenting cells 
One subset of immune cells, antigen presenting cells (APCs), are critical for the 
translation of innate signals into an adaptive immune response. These cells are 
important for activating T-cells. T-cells, unlike B cells, cannot directly interact with the 
pathogen they recognize. APCs activate T-cell by presenting antigen to T-cells and 
instructing them on the type of immune response they should potentiate. APCs such as 
DCs, macrophages, and B cells take up antigen or pathogens, either by phagocytosis or 
by infection. These APCs process the antigen or pieces of the pathogen into peptides 
and load the peptides into an MHC that is trafficked to the surface of the APC. The T-cell 
can than recognize the antigenic peptides in the MHC using its T-cell receptor (TCR). 
The TCR only recognizes specific peptides, therefore T-cells will only respond to specific 
pathogens, not broad patterns like innate cells using PRRs. 
  CD8+ T-cells only recognize peptides presented in MHC-I. Classically, 
endogenous antigen is loaded on the MHC-I from infected cells. Specialized machinery 
is required to process internalized exogenous antigen, such as inert vaccinated antigen 
acquired through phagocytosis, and load it onto to MHC-I42. The process of taking 
exogenous protein and loading it onto MHC-I is called cross-presentation and is critical 
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for CD8+ T-cell responses to subunit and killed vaccinations. CD4+ T-cells only 
recognize peptide loaded into MHC-II, which was classically thought to come from 
exogenous antigen, however, this process is more flexible than originally believed141. 
MHC-II is predominately expressed by APCs, while all cells express MHC-I.  
Contact between the TCR and the peptide-MHC complex is not enough to 
provoke an immune response. The APC must also instruct the T-cell how it should 
respond to an antigen. During an infection, the cytokines released by infected cells or 
direct sensing of PAMPs by the APCs inform them of the type of infection occurring142. 
Different pathogens can be recognized by different PRRs. For example, type I IFN 
stimulation indicates and intracellular infection. The APC recognizes an infection and 
upregulates co-stimulatory molecules expression on its surface, such as CD80 and 
CD86, and secretes cytokines such as type I IFN, IL-12, or IL-4 that are important for 
shaping T-cell responses. Peptide-MHC, co-stimulatory molecules, and cytokines act as 
signals 1, 2, and 3, respectively, and activate and skew T-cell responses. 
Different APCs have diverse functions during the cellular response. B cells do not 
typically activate naïve T-cells, instead their expression of MHC-II is primarily used to 
communicate with Tfh cells143. Tfh cells communicate with B cells and instruct antibody 
isotype switching by secreting cytokines specific for the type of antibody response 
required144. A second APC subset, macrophages, are increasingly found to be efficient 
activators of naïve T-cells, however, less is known about this function of macrophages 
and continued exploration is needed145. Instead, macrophages predominately act in the 
periphery and communicate with T-cells during the response to infections or 
vaccinations. DCs are the primary activators of naïve T-cells in the draining lymph 
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node61. DCs are critical for shaping the adaptive immune response by translating signals 
from the innate immune response and secreting cytokines that directly instruct T-cells on 
the adaptive immunity direction they should skew towards. DCs can be further divided 
into three subtypes, each with unique roles during an immune response. Conventional 
DC type 1 (cDC1) or type 2 (cDC2) and plasmacytoid DCs (pDCs).  
cDC1 are specialized to activate naïve CD8+ T-cells. cDC1 development 
requires the transcription factor BATF3146. Studies in Baft3-/- mice infected with West Nile 
virus146, cytomegalovirus147, influenza virus148, cowpox virus149, and others fail to induce 
CD8+ T-cell responses, underscoring the role of cDC1s for CD8+ T-cell response to 
infections. cDC1s are specially equipped to cross-present antigen61, making them a 
critical target for subunit and killed vaccinations. cDC1s take inert antigen and present it 
via MHC-I, a process that is up-regulated upon PRR stimulation and  type I IFN 
signaling150. cDC1s express high levels of TLR3, lack TLR7 expression, and express 
lower levels of RLRs than cDC2s67,151. This high expression of TLR3 in combination with 
phagocytosis of inert antigen increase cDC1s ability to sense viral RNA when it is 
endocytosed with antigen, ensuring a coordinated response.  
cDC2s are more efficient at MHC-II presentation and  naïve CD4+ T-cell 
activation than their cDC1 counterparts152. In contrast to cDC1s, there is no known 
cDC2-specific transcription factor that can be knocked out to solely deplete cDC2s153. 
Studies combining various knock outs or cell-type specific knock outs, such as Irf4f/f 
Itgax-cre can lead to loss of function of cDC2s or partial loss of cDC2s, but not total 
depletion154,155. Further work needs to be done to fully understand the direct role of 
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cDC2s during many infections. cDC2s express high levels of RLRs and are primed to 
become activated by infection by viruses151. 
pDCs express lower levels of T-cell activation machinery than their conventional 
counter parts and do not primarily function to active naïve T-cells156. However, pDCs are 
specially equipped to sense and combat viral infections. pDCs express high levels of 
endosomal nucleic acid sensing TLR7 and TLR9157. Upon sensing viral RNA, pDCs 
produce vast quantities of type I IFN156. As discussed above, type I IFN plays a 
pleotropic role during the induction of a type 1 immune response. The exact role of pDCs 
during infections and vaccinations is still under investigation but they are believed to aid 
in shaping the cytokine environment during infections.  
Together, DCs are important translators of innate immune sensing into signals 
that drive and shape adaptive immunity. Understanding what type of stimulus is required 
to active subsets of APCs is critical for tailored vaccine design. 
1.4 Defective viral genomes 
1.4.1 What are DVGs?  
 Defective viral genomes (DVGs) are replication products formed during viral 
infections. DVGs require the presence of a full-length viral genome in order to replicate 
and can come in many forms that are categorized based on their structure (summarized 
in Figure 1.2). Deletion DVGs lack sections of internal sequence but maintain the 5’ and 
3’ ends of the genome158,159. Snapback and copy-back DVGs (cbDVGs) are 
hypothesized to form when the polymerase is copying the viral genome, falls off, and 
rejoins the nascent strand, resulting in highly complementary genome ends. Snapback 
DVGs are almost entirely complementary in structure160, while cbDVGs contain longer 
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loops of internal non-complementary sequence161. DVGs are formed during infections 
with most viruses162,163, and different families of viruses form different dominate types of 
DVGs. Interestingly, DVGs are found in not only in viral stocks, but in live vaccine 
preparations for polio164, measles165, and influenza vaccines166.  
 
Figure 1.2. Types of DVGs.  Deletion 
DVGs are formed when the polymerase 
(grey) skips a section of the genome but 
leaves the genome ends intact. 
Snapback and copy-back DVGs are 
formed when the polymerase falls off the 
template and rejoins the nascent strand 
to form highly complementary genomes. 
Snapback DVGs are almost completely 
complementary in structure. Copy-back 
DVGs have loops of non-complementary 
sequence. Figure was created in 
BioRender.com. 
Paramyxoviridae is a family of negative sense single-stranded RNA viruses that 
includes viruses impacting human and veterinary health. Paramyxoviruses preferentially 
form cbDVGs. Sendai virus (SeV, murine parainfluenza virus 1) is a model 
paramyxovirus that has been extensively studied to understand paramyxovirus biology. 
The Cantell strain of SeV preferentially produces a single 546nt cbDVG in cell culture167.  
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Studies from the López lab have illustrated the critical role cbDVGs play as 
primary immunostimulatory molecules during paramyxovirus infections. In studies 
conducted with SeV, stocks of virus are grown that contain high levels of DVGs (HD) 
and low levels of cbDVGs (LD). In cell culture, IFNβ production completely relied on the 
presence of cbDVGs, regardless of the amount of virus used to infect to the cells168. 
During In vivo infections with LD and HD SeV stocks, cbDVGs protected mice from 
challenge and were responsible for type I IFN expression168,  highlighting the role DVGs 
have in inducing an immune response during infections.  
To tease apart the immunostimulatory capabilities of the 546nt SeV cbDVG, in 
vitro transcription was utilized. RNA fold predictions of cbDVG-546 show multiple hairpin 
and stem loops. Whether these structures exist during infections with nucleoprotein 
present is under investigation. One predicted stem loop composed of nucleotides 70-114 
is responsible for the majority of the immunostimulatory properties cbDVG-546169. 
Transferring the immunostimulatory motif to inert RNA such as the X-region from 
hepatitis C virus results in IFN induction, confirming the importance of the motif for the 
immunostimulatory properties of SeV DVG-546169. 
1.4.2 DVG-derived oligonucleotides 
Further cloning of SeV cbDVG-546 resulted in the creation of DVG-derived 
oligonucleotides (DDO). As the in vitro transcribed cbDVGs were capable of inducing 
RIG-I-dependent  type I IFN expression169, the López lab next asked if the innate 
immune response induced by DDO could be translated into an adaptive immune 
response upon vaccination. Early studies used a prototype 324nt DDO. Highly 
concentrated injections (50µg) of prototype DDO induced cytokine responses in the 
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injected tissue that differed from poly I:C170. Prototype DDO also increased the number 
of DCs recruited to the draining lymph node and resulted in an antigen specific IgG2b 
response in vaccinated mice170.  
The 324nt DDO was further shortened to 268nt. The 268nt DDO is completely 
replication incompetent as it lacks the genomic region required for SeV polymerase-
dependent replication169. DDO contain the DVG immunostimulatory motif and the 
structure is further stabilized by increased base pairing. DDO are more 
immunostimulatory than the full length 546nt DVG169 and could be a useful tool to tease 
apart early steps in the induction of immune responses.  
1.5 Experimental questions 
The López lab has long studied cbDVGs and their role in the induction of immune 
responses to paramyxovirus infections. During infections, many signals and stimuli 
coincide with virus replication and cell death. By studying the immunostimulatory 
molecule outside the context of infection, we have a powerful tool to tease apart 
individual signals that lead to immune responses and use this knowledge to design more 
specific and effective vaccines tailored to the pathogens they are designed to protect 
against. 
DDO offer a unique tool to further investigate the induction of immune responses. 
DDO are small, simple RNA molecules that closely mimic PAMPs produced during virus 
infection. DDO allow us to examine the role specific signals play during initiation of 
immune responses. Based on the in vitro and in vivo immunostimulatory properties of 
the 324nt DDO prototype we hypothesize that the 268nt DDO (referred to as DDO from 
here) act as a type 1 immunity-inducing adjuvant. Through studying the early response 
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to DDO, we can understand the requirements for inducing a type 1 immune response 
during vaccination.  
In Chapter 2, we investigated the use of DDO as a type 1 immunity-inducing 
adjuvant. We first determined whether DDO induced the hallmarks of type 1 immune 
responses during influenza vaccination in mice. We next examined the effector capacity 
of CD8+ T-cells activated in response to DDO-adjuvanted vaccines. Lastly, we tested 
whether DDO could synergize with AddaVax, an adjuvant that induces mixed type 1/ 
type 2 immunity and skew the immune response towards more robust type 1 immunity.  
In chapter 3, we investigated the induction of an immune response to DDO 
injection. We examined the DC response to DDO injection and determined the kinetics 
of DC recruitment to the draining lymph node. We investigated the early cytokine 
response to DDO injection and the role of type I IFN in DDO’s ability to activate DCs. 
Finally, we determined how DDO was sensed and the role this sensor played for T-cell 
activation.  
In summary, we used a simple virus-derived RNA adjuvant to tease apart the 
early steps in the induction of an immune response. Overall, this work defines the early 
steps that are required to induce a type 1 immune response to vaccination and can be 
used to design more tailored and effective vaccines. 
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CHAPTER 2: Virus-derived immunostimulatory RNA induces type I 
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Adjuvants potentiate and direct the type of immunity elicited during vaccination. 
However, there is a shortage of adjuvants that elicit robust type 1 immunity required for 
the control of intracellular pathogens including viruses. RNA derived from Sendai virus 
defective viral genomes (DVGs) stimulates RIG-I-like receptor signaling leading to type 1 
immunity during infection. Here, we investigated whether a 268nt DVG-derived 
oligonucleotide (DDO) functions as a strong type 1 immunity-inducing adjuvant during 
vaccination against influenza virus. We show that DDO induces robust IgG2c antibody 
production when used in an inactivated influenza A virus (IAV) vaccine. Additionally, 
DDO induces Th1 and CD8+ T-cell responses able to protect against heterosubtypic IAV 
challenge. Interestingly, DDO synergized with AddaVax and skewed the immune 
response towards type 1 immunity. The adjuvancy of DDO alone and in synergy with 
AddaVax was heavily dependent on type I interferon signaling. Our data support a 
critical role for type I interferon in the induction of type 1 immune responses during 
vaccination and demonstrate that DDO is a type 1 immunity orienting vaccine adjuvant 
that can be used alone or in synergy with other adjuvants. 
2.2 Introduction 
Subunit and inactivated vaccines are ideal for vaccine development because 
they do not revert to virulence and are unlikely to cause disease in immunocompromised 
individuals. Unfortunately, inactivated and subunit vaccines lack the danger signals 
required to induce robust adaptive immunity. Thus, adjuvants that boost and shape the 
immune response towards vaccinated antigens are added to improve vaccine efficacy. 
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Currently, there are no licensed vaccine adjuvants that induce robust type 1 
immunity7,171–173. Type 1 immune responses are important for the control of viruses and 
other intracellular pathogens and are characterized by the generation of cytotoxic CD8+ 
T-cells, Th1 CD4+ T-cells, and antibodies of the isotypes IgG2b/c174,175. Induction of type 
1 immunity is also critical for pathogens where induction of other types of immunity lead 
to enhanced pathogenesis. For example, infants with type 2 immunity-primed lungs 
suffer from increased morbidity when infected with respiratory pathogens including 
respiratory syncytial virus (RSV) or rhinovirus51,176,177. 
Alum, the oldest and most widely used vaccine adjuvant, induces robust type 2 
immunity. While effective against extracellular pathogens, type 2 immunity does not 
protect against most intracellular pathogens13. In addition to alum, the TLR4 ligand 
monophosphoryl lipid A (MPL) absorbed onto alum, named adjuvant system04 
(AS04)178, and oil-in-water emulsions, such as MF59, are approved for use in human 
vaccines13. These can induce protective antibodies and mild Th1 responses, but no 
approved vaccines use these adjuvants to induce protective CD8+ T-cell responses13.  
Many type 1 immunity-inducing adjuvant candidates utilize pathogen associated 
molecular patterns (PAMPs) recognized by pattern recognition receptors including Toll-
like receptors (TLRs) and RIG-I-like receptors (RLRs)179,180. The use of natural PAMPs 
more closely mimics the immune responses obtained during infections, such as the 
induction of type I interferon (IFN). In addition to MPL used in AS04, synthetic PAMPs 
have been examined as potential type 1 immunity inducing adjuvants. These include the 
viral RNA mimic poly I:C., which failed to induce strong type 1 immune responses 
without toxicity99, and CpG, which is used in a combination adjuvant181. Notably, 
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emulsions provide an ideal platform for adjuvant synergy and the combinatorial effects of 
using multiple adjuvants in a single vaccine can be exploited to generate optimized 
adjuvants.  
We previously identified a Sendai virus PAMP originating from a copy-back 
defective viral genome (DVG) naturally generated during viral replication168 and 
characterized the immunostimulatory RNA motif responsible for recognition by RLRs169. 
Subcutaneous injection of a shortened synthetic version of this 546nt DVG (DVG-324) 
resulted in a local and distinct cytokine profile from polyI:C170. Additionally, DVG-324 
promoted the accumulation of DCs in draining lymph nodes of mice. Mice vaccinated 
with DVG-324 and inactivated RSV developed type 1 immunity-associated antibody 
responses170. Additional work indicated an important role for RLRs for the induction of 
protective immunity in DVG-546-adjuvanted vaccines182. These studies suggest that 
derivatives of this molecule are valuable candidates for type 1 immunity inducing 
adjuvants.  
Here we report a 268nt DVG-derived oligonucleotide (DDO) with enhanced 
immunostimulatory capabilities in vitro169. We demonstrate its ability to induce protective 
type 1 humoral and cellular immune responses during immunization with whole 
inactivated influenza A virus (inIAV) or a HA-subunit vaccine. Additionally, we show that 
DDO synergizes with AddaVax (the research version of MF59) to induce potent type 1 
polarized immune responses and that both humoral and Th1 responses elicited by 
vaccines adjuvanted with DDO rely on type I IFN. 
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2.3 Materials and Methods 
2.3.1 Ethics statement 
Studies in mice were carried out in strict accordance with the recommendations 
in the Guide for the Care and Use of Laboratory Animal of the National Institute of 
Health. The protocol (804691) was approved by the Institutional Animal Care and Use 
Committee, University of Pennsylvania Animal Welfare Assurance Number A3079-01. 
2.3.2 Mice and Viruses  
C57BL/6 mice (6-8 weeks old) were obtained from Jackson Laboratory. Ifnar1-/- 
mice183 were a kind donation of Dr. Thomas Moran (Icahn School of Medicine at Mount 
Sinai) and were used with gender and age matched C57BL/6 mice (Jackson Laboratory 
bred in house). All experiments were performed in male and female mice. Influenza A/X-
31 H3N2 (IAV X-31) and A/California/7/2009 H1N1 with D225G HA mutation (IAV-
Cal/09-D225G) that allows the wild-type A/California/7/2009 virus to grow in eggs184 
were used as challenge strains. All strains of IAV were grown in 10 day-old embryonated 
chicken eggs (Charles River Laboratory) at 30,000 medium tissue culture infectious 
dose (TCID50) at 37°C. Allantoic fluid from infected eggs was collected 40h later.  
2.3.3 Vaccine formulations 
Inactivated IAV (inIAV) vaccine: Influenza A/Puerto Rico/8/1934 H1N1 (IAV 
PR/8) was harvested from allantoic fluid of 10 day old embryonated eggs and purified 
through a 35% sucrose cushion. Virus was inactivated with UV light (254nm at 6-inch 
distance) for 40 minutes. Inactivation was confirmed by the inability of the virus to 
replicate in MDCK cells (Madin-Darby canine kidney cells, gift from Dr. Scott Hensley, 
University of Pennsylvania) in the presence of 2mg/ml trypsin. The inIAV vaccine had a 
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total protein concentration of 989µg/ml, HA titer of 10240U/ml at a 1:100 dilution and an 
endotoxin level of <1.2EU/ml. Recombinant IAV-HA protein from IAV-Cal/09-D225G 
used as a subunit vaccine was obtained from BEI Resource (NR-13691). DDO is a 
268nt non-coding, replication-incompetent ssRNA sequence that contains the 
immunostimulatory DVG-motif identified and characterized previously169,170 . DDO was 
produced, stored, and used as previously described169. Purity and integrity of DDO were 
confirmed using an Agilent Bioanalyzer 2100 and had an OD260/280 ratio of 2.16, an 
OD260/230 ratio of 2.3, and endotoxin level below 0.1EU/ml/300ug. 
2.4.3 Mouse immunization and challenge 
For immunization, mice were anesthetized with isoflurane and injected 
intramuscularly (i.m.) into the thigh with 10µg inIAV vaccine or 1µg recombinant IAV-HA 
protein diluted in PBS adjuvanted with 5µg DDO, AddaVax (InVivogen) at 50% v/v, or 
Alum (Alhydrogel 2%, InvivoGen) at 50% v/v at final volume of 50µl per dose 
manufacturer recommendations. Mice were primed and boosted 14 days later with the 
same vaccine formulation. In some experiments, mice were challenged intranasally with 
103.5 TCID50 of IAV X-31 (heterosubyptic challenge) or 2x104 TCID50 of IAV-Cal/09-
D225G 21 days after boost. All mice were weighed daily post-challenge. Lung tissue 
was harvested 4 or 10 days post-challenge for viral load quantification or histology. 
2.3.5 Viral load quantification  
IAV titration was performed by limiting dilution in MDCK cells as previously 
described170. For quantifying IAV-NP transcripts in lung homogenate, 1-2µg of RNA 
isolated by TRIzol (Invitrogen) was reversed transcribed using high capacity RNA to 
cDNA reagents (Applied Biosystem). qPCR assays were performed using SYBR Green 
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PCR Master Mix (Applied Biosystem) in a Viia7 Applied Biosystem Lightcycler. Primers 
used in the assay were: Gapdh for-5’-ctcccactcttccaccttcg-3’ and rev-5’-
ccaccaccctgttgctgtag-3’ and IAV-NP for-5’-cagcctaatcagaccaaatg-3’ and rev-5’-
tacctgcttctcagttcaag-3’. 
2.3.6 Quantification of influenza-specific serum antibodies  
Sera from immunized mice were analyzed for anti-IAV total IgG, IgG1, and IgG2c 
antibodies on day 14 post-boost using ELISA to evaluate peak antibody response170. 
Briefly, sera pre-diluted (1:100, 1:1000, and 1:10,000) were added in triplicate to ELISA 
plates (Immulon, 4 HBX Extra High Binding) coated with 5µg/ml purified IAV or 2µg/ml 
IAV HA protein (BEI Resource, #NR-13691) followed by HRP-conjugated anti-mouse 
IgG, IgG1, and IgG2c (Southern Biotech) and ABTS substrate (Roche).  
2.3.7 Flow cytometry 
Single-cell suspensions of spleen and inguinal lymph node were prepared and 
stained with fluorochrome-labeled antibodies as previously described185. LIVE/DEAD 
Fixable Near-IR Dead stain was obtained from Invitrogen. Fixable Viability Dye 
eFluor506, monoclonal antibody specific for mouse CD8 (clone 53-6.7), IFN (clone 
XMG1.2), and TNFα (clone MP6-XT22) were obtained from eBioscience. Monoclonal 
antibodies specific for mouse CD3 (clone 17A2), CD4 (clone GK1.5), CD11a (clone 
H11578), CD44 (clone IM7) and MHC-II (clone M5/114.15.2) were obtained from 
Biolegend. Monoclonal antibodies specific for mouse CD8 (clone 53-6.7) were obtained 
from BD BioSciences. IAV-specific tetramers:  H-2Db tetramers bearing NP336-374 
(ASNENMETM) and I-Ab tetramers bearing NP311-325 (QVYSLIRPNENPAHK) were 
obtained from NIH Tetramer Core Facility at Emory University. Samples were acquired 
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on a LSRFortessa (BD Bioscience) cytometer and analyzed using the FlowJo Software 
(TreeStar). We restimulated splenocytes using PMA (0.1mg.mL) and Ionomycin 
(1mg/ml) for 4 hours at 37°C. 
2.3.8 Lung Pathology 
On day 10 post heterosubtypic challenge, the left lobe of the lung was inflated 
and fixed with 1ml of 10% buffered formalin solution. Fixed lungs were paraffin-
embedded and sectioned using standard procedures. Lung sections were cleared of 
paraffin and Periodic acid–Schiff (PAS) stained. Lung sections were blinded and small 
airways were scored. Epithelial metaplasia severity was scored according to the 
following scale: 0, no metaplasia; 1, mild (2 layers); 2, moderate (3 layers); 3, severe (>4 
layers). Percent of airways experiencing epithelial metaplasia were scored: 0, no 
airways; 1, <25% of airways; 2, 26-50%; 3, 51-75%; 4, >75%. Goblet cell hyperplasia 
severity was scored: 0, none; 1, <10 PAS+ cells/airway; 2, 10-20 cells; 3, >20cells. 
Percent of airways experiencing hyperplasia were scored; 0, no airways; 1, <10%; 2,10-
20%; 3, 20-40%; 4, >40%.  
2.3.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 for Mac (GraphPad 
Software). RT-qPCR and flow cytometry data were analyzed by one-way ANOVA 
followed by Bonferroni’s multiple comparison. Weight-loss and ELISA data were 




2.4.1 DDO is a thermostable small RNA with strong immunostimulatory activity. 
 DDO containing a previously described motif responsible for its 
immunostimulatory activity (Figure 2.1A) are stable at -80°C for more than a year169. To 
test the stability of DDO across multiple vaccination-relevant temperatures, DDO were 
stored at 4°C, room temperature (26°C/RT), or 37°C for up to 48h and analyzed for 
degradation using a Bioanalyzer. DDO showed no appreciable degradation at any of the 
conditions tested (Figure 2.1B). To test for immunostimulatory activity, RNA stored at 
each condition was transfected into cells and cells were examined by RT-qPCR for the 
expression of IL29 (also known as IFN) and the IFN-stimulated gene IFIT1, two early 
indicators of antiviral activity. After 8h of incubation at different temperatures, DDO was 
as immunostimulatory as DDO stored at -80°C. After 24h, while there was no visible 
degradation, IL29 expression slightly decreased in all 3 conditions, but DDO remained 
more immunostimulatory than the HCV X-region, a similarly structured RNA lacking 
immunostimulatory capabilities (Figure 2.1C). Interestingly, the levels of IFIT1 remained 
constant across all DDO conditions and time points indicating that the slight decline in 
primary IFN production observed did not impact downstream gene expression (Figure 
2.1D). 
2.4.2 DDO promotes an IgG2c-biased antibody response and T-cells associated with 
type 1 immunity 
To assess whether DDO-adjuvanted vaccines enhance adaptive immunity 
against vaccinated antigens, we evaluated the antibody response generated against IAV 
14 days after boost immunization with inIAV alone or adjuvanted with DDO or alum. 
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While alum induced a type 2 immunity-associated IgG1 response, DDO significantly 
enhanced the type 1 immunity-associated IgG2c response (Figure 2.2A).  
To assess how DDO influence the T-cell response, spleens and draining 
(inguinal) lymph nodes were harvested 7 days post-boost immunization. Mice that 
received DDO-inIAV had significantly more TNFα+ IFNγ+ Th1 cells in the spleen (Figure 
2.2B-C) and draining lymph node (Figure 2.2D) than mice immunized with alum-inIAV or 
inIAV alone. Additionally, DDO-inIAV-vaccinated mice had significantly more IAV-specific 
CD8+ T-cells (Figure 2.2E). Together, these results demonstrate that DDO induces type 
1 immunity when used as a vaccine adjuvant.  
2.4.3 Immunization with DDO adjuvant induces long-term CD8+ T-cell protection against 
heterosubtypic challenge 
 We next evaluated the longevity and effectiveness of CD8+ T-cell responses 
induced by DDO. Mice immunized with DDO-inIAV had significantly more IAV-specific 
CD8+ T-cells on day 46 post-boost than mice immunized with alum-inIAV or inIAV alone 
(Figure 2.3A). To better understand the effector capabilities of the CD8+ T-cells induced 
by DDO-adjuvanted vaccines, mice were challenged with heterosubtypic IAV differing 
only in external hemagglutinin (H) and neuraminidase (N) proteins. As internal proteins 
are not targeted for antibody neutralization, heterosubtypic challenge after immunization 
heavily relies on CD8+ T-cells for clearance and recovery. Mice immunized with inIAV 
PR/8 (H1N1) were challenged 21 days after-boost with IAV X-31 (H3N2). Mice 
immunized with DDO-inIAV recovered more quickly than mice immunized with alum-
inIAV or inIAV alone (Figure 2.3B).  
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To characterize the pathology induced upon infection in the absence of 
neutralizing antibodies, lungs were harvested 10 days post-heterosubtypic challenge 
and PAS stained. Magenta PAS staining indicates mucus and mucus-containing cells 
such as goblet cells, a characteristic of type 2 immunity associated pathology. Both 
inIAV and alum-inIAV-vaccinated mice showed stronger PAS staining and goblet cell 
hyperplasia compared to DDO-inIAV (Figure 3C-D). Additionally, alum-treated mice had 
airway thickening and increased epithelial cell metaplasia (Figure 2.3C, E). Together, 
these results indicate that DDO adjuvants induce long lasting protective CD8+ T-cell 
responses without type 2 immunity-associated pathology.  
2.4.4 DDO synergizes with AddaVax to skew immunity towards protective type 1 
immune responses upon subunit vaccination 
 AddaVax, the research version of MF59, induces a mixed type 1 and type 2 
immune response. As adjuvant synergy is a promising approach to improve and shape 
immune responses after vaccination7, we next tested whether DDO and AddaVax 
synergized. DDO+AddaVax-adjuvanted immunizations boosted the IgG response above 
those of mice immunized with either adjuvants or HA alone. More importantly, in a 
subunit vaccine, DDO significantly increased IgG2c antibody induction when combined 
with AddaVax (Figure 2.4A). While both AddaVax-HA and DDO+AddaVax-HA protected 
from significant weight loss (Figure 2.4B), DDO+AddaVax-HA better protected mice from 
viral replication measured by the expression of viral NP RNA in lung homogenates on 
day 4 post-challenge (Figure 2.4C). Together, these results show that Addax and DDO 
synergize to induce potent protective humoral immunity characterized by IgG2c 
antibodies upon subunit IAV vaccination.  
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2.4.5 DDO relies on type I IFN to induce humoral and cellular immunity.  
 DDO potently induce type I IFN in vitro169. To begin to understand the 
mechanism of action of DDO adjuvants, we immunized wild-type (WT) or Ifnar1-/- (KO) 
mice with inIAV alone or adjuvanted with DDO, AddaVax, or DDO+AddaVax. On day 14 
post-boost immunization, DDO-inIAV immunized mice required type I IFN for IgG1 and 
IgG2c antibody production (Figure 2.5A). Interestingly, all other vaccine formulations 
required type I IFN only for IgG2c induction. These results indicate that IFN is critical to 
induce an IgG2c response across adjuvant formulations and for DDO-induced antibody 
responses in general.  
To explore the role of type I IFN in the induction of Th1 cells, we vaccinated mice 
as described above and harvested spleens and draining lymph nodes on day 7 post-
boost. Consistent with the dependence on type I IFN for antibody induction, TNF+IFNγ+ 
Th1 cells in the spleens (Figure 2.5B) or lymph nodes (Figure 2.5C) required type I IFN 
when adjuvanted in the presence of DDO. 
To test whether type I IFN is required for protection against heterosubtypic 
infection, mice from Figure 5A were challenged with heterosubtypic IAV (H3N2) on day 
21 post-boost. WT mice vaccinated with DDO+AddaVax-inIAV recovered more rapidly 
than AddaVax-inIAV and DDO-inIAV immunized mice (Figure 2.5D), suggesting that 
DDO synergized with AddaVax to improve heterosubtypic protection. This synergy relied 
significantly on type I IFN, while immunization in the presence of DDO alone was less 
dependent on type I IFN to promote recovery from heterosubtypic challenge (Figure 
2.5D bottom panel, days 8 and 14 post-challenge). Together, these results indicate that 
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type I IFN is crucial to induce protective cellular immunity upon DDO+AddaVax-
adjuvanted vaccinations. 
2.5 Discussion 
The lack of type 1 immunity-inducing adjuvants has hindered the development of 
non-replicative vaccines against intracellular pathogens. Here we show that DDO is an 
excellent candidate for further development as a type 1 immunity-inducing adjuvant. 
DDO is a stable, homogenous, and replication-incompetent 268nt-long RNA 
oligonucleotide. DDO is created using in vitro transcription, a process amenable to mass 
production. This RNA adjuvant is safe in mice170 and induces the hallmarks of type 1 
immune responses: Th1 cells, CD8+ T-cells, and IgG2c antibodies. 
 A new strategy in the vaccination field is to combine adjuvants to boost and skew 
immune responses13. AddaVax, the research equivalent of the licensed oil-in-water 
emulsion adjuvant MF59, induces a mixed type 1/type 2 immune response7,172,186. We 
combined AddaVax and DDO to take advantage of the type 1 skewing properties of 
DDO to achieve a strong, protective type 1 response in a model IAV vaccine. Using a 
subunit vaccination approach (HA protein), we show that DDO+AddaVax synergize to 
induced more robust immune responses than each individual adjuvant alone.  This 
synergy resulted in skewed the humoral response towards IgG2c and better protect from 
challenge. In an inactivated virus vaccination approach, DDO+AddaVax synergy 
protected from heterosubtypic challenge and increased T-cell responses better than 
DDO alone. Interestingly, the synergy appears to use different mechanisms for whole 
virus and protein, which could be due to intrinsic adjuvancy from inIAV as it still contains 
RNA genomes that could act as a PAMP. 
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 DDO efficacy relies heavily on type I IFN for Th1 induction and humoral 
responses. Despite this, protection from heterosubtypic challenge did not require type I 
IFN signaling. In contrast, the enhanced heterosubtypic protection by DDO+AddaVax 
synergy relied on type I IFN. The different requirement for type I IFN signaling further 
supports the hypothesis of a different mechanism of action for DDO alone and in 
combination with AddaVax. It is possible that DDO+AddaVax combinations may result in 
enhanced and distinct local and/or systemic inflammation. Potentially, AddaVax could 
deliver DDO to different cells or lead to different intracellular localization compared to 
DDO alone. Secondary effects of DDO used in combination with AddaVax should be 
carefully evaluated.  
Type I IFN strongly promotes type 1 immunity during viral infections by 
enhancing DC maturation and trafficking, positively regulating effector and memory Th1 
CD4+ T-cell generation, supporting CD8+ T-cell priming, and instructing isotype 
switching to IgG2c109,187,188. Interestingly, the few available T-cell-inducing vaccine 
adjuvants rely on the cytokines IL-12 or IL-27 rather than IFN189. However, the 
experimental adjuvant chitosan, which promotes cellular immunity through the DNA 
sensor cGAS-STING, also relies on IFN signaling190. Understanding how type I IFN is 
being induced, sensed, and what cells produce it is important to understand the 
mechanisms of DDO adjuvancy. A better understanding of the requirements of a type 1 
immunity inducing vaccine adjuvant could lead to more informed design of vaccines for 
intracellular pathogens.  
In summary, the antibody isotype induction, T-cell cytokine production, and 
protection from heterosubtypic challenge demonstrated here with DDO-adjuvanted 
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vaccines illustrate the ability of this molecule to induce type 1 immunity and its potential 






Figure 2.1. DDO-268 is a thermostable small RNA with strong 
immunostimulatory activity. (A) DDO is a 268 nucleotide single-stranded RNA with 
an immunostimulatory motif shown in its secondary structure together with its 
sequence. DDO were incubated at 4°C, room temperature (26°C/RT), or 37°C for 8h, 
24h, or 48h. (B) Integrity of the RNA was analyzed using electrophoretic analysis on a 




qPCR from A549 cells transfected for 6h with 4.15pmo DDO used in (B). The 
experiment was repeated 3 times with a single representative repeat shown here. 
Data are expressed as copy numbers relative to the housekeeping gene GAPDH, 





Figure 2.2. DDO promotes type 1 immunity. C57BL/6 mice immunized on day 0 
and day 14 with 10µg of UV-inactivated IAV PR/8 (inIAV) alone or adjuvanted with 
5µg DDO or with 50% v/v Alum. (A) H1N1-IAV specific IgG1 and IgG2c antibodies 
in sera of mice on day 14 post-boost. Data correspond to the mean±SEM of ELISA 
at 1:1000 and 1:10000 dilution point from the sera of vaccinated mice (n=5/group). 
**p<0.01, ***p<0.001, ****p<0.0001 by two-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. (B-E) Antigen-experienced cells in the spleen and 
draining lymph nodes were examined on day 7 post-boost using flow cytometry. (B) 
Representative flow cytometry plots for IFN+ TNF+, CD11a+CD4+ T-cells from the 
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spleens of vaccinated mice. IFN+ TNF+ were identified by gating on live, singlets, 
CD3+, CD4+CD8-, CD11a+ cells. (C) Percentage of IFN+ TNF+, CD4+ T-cells in the 
spleens of individual mice in each vaccination group after PMA/Ionomycin 
restimulation. (D) Percentage of IFN+ TNF+, CD4+ T-cells in the draining lymph 
nodes of individual mice in each vaccination group after PMA/Ionomycin 
restimulation. (E) Percentage CD11a+Tetramer+ (NP336-374) CD8+ T-cells from the 
spleens of individual mice in each vaccination group. Percentage of was quantified 
by intracellular cytokine staining after gating on live, singlets, CD3+, CD4-CD8+, 
CD11a+.Data correspond to individual mice with mean±SEM (n=5/group). 






Figure 2.3. DDO promotes long-term CD8+ T-cell memory and heterosubtypic 
immunity to IAV after prime-boost immunization. (A) Percentage of IAV-tetramer 
specific CD8+ T-cells in the spleens of mice on day 46 post-boost with 10µg of inIAV 
alone or adjuvanted with 5µg DDO or 50% v/v Alum. Tetramer+CD44+ positive cells were 
identified after gating on singlets, live, CD3+CD4-CD8+ cells. Data correspond to 
individual mice with mean±SEM (n=5/group). *p<0.05, **p<0.01 by one-way ANOVA with 
Bonferroni’s multiple comparison test. (B-E) Mice were challenged with 103.5 TCID50 IAV-
X31 (H3N2) intranasally on day 21 after boost immunization. (B) Weight loss. Data 
correspond to mean±SEM of each group (n=5/group). *p<0.05, **p<0.01, ***p<0.001 by 
two-way ANOVA with Bonferroni’s multiple comparison test. * compares DDO to controls 
(--). + compares DDO to Alum. (C) Representative images of paraffin-fixed PAS stained 
lungs on day 12 post-infection. Magenta staining indicates mucus positive cells. Scale 
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bar=100m. (D) Weighted score of goblet cell hyperplasia calculated by multiplying the 
score for amount of airways affected by the intensity score and divided by 100. (E) 
Weighed score of epithelial cell metaplasia scored as in (D). Statistics by T test between 






Figure 2.4. DDO and AddaVax synergize to induce protective antibodies of the 
isotype IgG2c to a protein (HA) vaccine. (A) IAV H1N1-HA specific IgG, IgG1, and 
IgG2c antibodies in the sera of C57BL/6 mice two weeks after a second i.m. 
immunization with 1µg HA protein alone (--) or adjuvanted with 50% v/v AddaVax, 
50% v/v AddaVax plus 5µg DDO (DDO+AddaVax), or 5ug DDO. Data correspond to 
the mean±SEM of ELISA at 1:1000 and 1:10000 dilution point from the sera of and 
vaccinated mice (n=5/group)., **p<0.01, ***p<0.001, ****p<0.0001 by two-way ANOVA 
with Bonferroni’s multiple comparison test. (B-C) Mice were challenged with 2104 
TCID50 of IAV-Cal/09-D225G three weeks after immunization. (B) Weight loss. 
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**p<0.01, ***p<0.001 and ****p<0.0001 by two-way ANOVA with Bonferroni’s multiple 
comparison test. * compare to controls (--), + compare to DDO. (C) Expression of IAV-
NP RNA Relative to Gapdh mRNA in lung homogenate of the mice 4 days after 
challenge was analyzed by RT-qPCR.  Data correspond to mean±SEM of individual 







Figure 2.5. DDO adjuvancy depends on type I IFN signaling. Wild-type (WT) and 
Ifnar1-/- (KO) C57BL/6 mice were immunized i.m. at day 0 and 14 with 10µg of inIAV 
alone (--) or adjuvanted with 50% v/v AddaVax, 5µg DDO, or 50% v/v AddaVax plus 5µg 
of DDO (DDO+AddaVax). (A) IAV specific IgG, IgG1, and IgG2c antibodies in the sera of 
WT (solid bars) and KO (striped bars) mice two weeks after boost immunization. Data 
correspond to the mean±SEM of ELISA at a 1:1000 dilution point from the sera of 
vaccinated mice (n=3-4/group)., *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by two-way 
ANOVA with Bonferroni’s multiple comparison test. (B) Percentage of IFN+ TNF+, 
58 
 
CD4+ T-cells in spleens was quantified by intracellular cytokine staining after gating on 
live, singlets, CD3+, CD4+CD8-, PMA/Ionomycin restimulated cells. Data correspond to 
individual mice with mean±SEM (n=3-4/group) *p<0.05, **p<0.01 by one-way ANOVA 
with Bonferroni’s multiple comparison test. (C) Percentage of IFN+TNF+, CD4+ T-cells 
in inguinal lymph nodes was quantified as in (B). Data correspond to pooled 3-4 lymph 
nodes. (D) Mice were challenged with 103.5 TCID50 IAV-X31 (H3N2) intranasally on day 
21 after boost immunization. Weight loss for WT mice (solid line and symbol) and KO 
mice (dashed line and half black symbol) is shown. Bottom panel: weight loss on days 8 
and 14 post-heterosubtypic challenge of WT (solid bars and symbols) and KO (striped 
bars and half black symbols) from data in top panel. Data correspond to the mean±SEM 
and show individual mice. + indicates no mice survived to time point. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 by two-way ANOVA with Bonferroni’s multiple comparison test.  
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CHAPTER 3: Defective viral genome-derived RNA activates TLR3 and 
type I IFN signaling to induce cDC1-dependent CD8+ T-cell responses 
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There is a critical need to create vaccine adjuvants that induce robust immune 
responses able to protect from intracellular pathogens. Previously, we described the 
virus-derived adjuvant defective viral genome-derived oligonucleotide (DDO) as a strong 
inducer of type 1 immune responses, including Th1 CD4+ T cells and effector CD8+ T 
cells in mice. Here we unravel the early innate response required for this type 1 
immunity induction. Upon DDO subcutaneous injection, type 1 conventional dendritic 
cells (cDC1s) accumulate rapidly in the draining lymph node in a type I interferon (IFN)-
dependent manner. cDC1 accumulation in the lymph node is required for antigen-
specific CD8+ T-cell responses. Notably, differently from poly I:C, DDO administration 
resulted in type I IFN expression at the injection site, but not in the draining lymph node. 
Additionally, DDO induced a unique inflammatory cytokine profile from poly I:C, despite 
both poly I:C and DDO being sensed by TLR3. Therefore, DDO represent a safe and 
powerful new adjuvant to be used during vaccination.   
3.2 Introduction 
Over the last few decades, vaccines have saved countless lives1. However, 
recent epidemics and pandemics have highlighted the continued need for vaccines 
against newly emerging pathogens. The development of new vaccines is constrained by 
safety issues and by our ability to tailor vaccines to develop the right type of immune 
response able of controlling and eliminating the target pathogen. Attenuated vaccines, 
while capable of inducing robust immune responses that mimic those generated during 
natural infections, present challenges due to their ability to revert to virulence or cause 
disease in a growing population of immunocompromised people6. Killed or subunit 
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vaccines offer a safer alternative to attenuated vaccines, however, they require an 
adjuvant to induce protective immune responses. Adjuvants not only boost the immune 
response to vaccinated antigens, but also shape the induced immune response.  
Type 1 immunity, including robust CD8+ T-cell responses, is critical for clearance 
of many intracellular pathogens. However, currently we lack adjuvants capable of 
inducing effective CD8+ T-cell responses thereby limiting our ability to develop effective 
vaccines against many intracellular pathogens. Type 2 immunity is commonly induced 
by existing adjuvants and consists of antibodies and Th2 CD4+ T-cells. This type of 
response can be detrimental to the host during many infections. For example, early trials 
for SARS-CoV-1 vaccines used alum, a type 2 immunity-inducing adjuvant, and resulted 
in worsened morbidity after challenge53. Type 2 immune responses induced upon 
respiratory syncytial virus (RSV) vaccination or infection lead to worsened disease or 
even death51,52,191. Similar findings were observed with rhinovirus infections in 
infants176,177. These observations highlight the importance of developing adjuvants that 
induce type 1 immune responses upon vaccination against these pathogens. In order to 
develop effective type 1 immunity-inducing adjuvants, we first must understand what 
early steps are required during vaccination to lead to a CD8+ T-cell response. 
We have shown that a virus-derived RNA adjuvant named defective viral 
genome-derived oligonucleotide (DDO) induces a robust type 1 immune response in 
mice. This response synergizes with other licensed adjuvants and induces effector CD8+ 
T-cells leading to faster recovery from heterosubtypic influenza challenge192. DDO are a 
synthetic and replication-incompetent 268nt RNA derived from the 546nt Sendai virus 
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(SeV) defective viral genome (DVG) that is the primary immunostimulatory molecule 
during SeV infections169,170.  
In this study, we asked how DDO was able to induce antigen-specific CD8+ T-
cell responses. We investigated the type of dendritic cells (DCs) activated in response to 
DDO injection and if those DCs were critical for a CD8+ T-cell response. We next 
investigated the local cytokine response at the injection site and the draining lymph node 
to better understand the early response that leads to type 1 immunity. Finally, we 
uncovered how DDO was sensed by cells to induce an immune response to DDO-
adjuvanted vaccines. Together, this study helps build our understanding of how the early 
innate immune response to a type 1 immunity inducing adjuvant leads to robust adaptive 
immunity.   
3.3 Materials and Methods 
3.3.1 Ethics statement 
All described studies carefully adhered to the recommendations in the Guide for 
the Care and Use of Laboratory Animal of the National Institute of Health. Institutional 
Animal Care and Use Committee, University of Pennsylvania Animal Welfare Assurance 
Number A3079-01 approved protocol 804691. 
3.3.2 Mice 
C57BL/6 mice were obtained from Jackson Laboratory. Ifnar1-/- mice were a kind 
donation of Dr. Thomas Moran (Icahn School of Medicine at Mount Sinai)183 and were 
used with sex and age matched C57BL/6 mice (Jackson Laboratory bred in house). 
Mavs-/- mice (B6;129-Mavstm1Zjc/J) and WT control recommended by Jackson labs 
(B6129SF2/J) were purchased from Jackson Laboratory. Tlr3-/- mice (B6;129S1-
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Tlr3tm1Flv/J) and WT control recommended by Jackson laboratory (B6129SF2/J mice) 
were purchased from Jackson Laboratory. Tlr7- (B6.129S1-Tlr7tm1Flv/J) and WT control 
recommended by Jackson laboratory (C57BL/6NJ) were purchased from Jackson 
Laboratory. Batf3-/- mice were a kind gift from Dr. Christopher Hunter (School of 
Veterinary Medicine at the University of Pennsylvania). All mice used were 6 to 8 weeks 
old at the start of the experiment. All experiments were performed with male and female 
mice. 
3.3.3 Vaccine formulation 
Disrupted IAV (disIAV) vaccine: Influenza A/Puerto Rico/8/1934 H1N1 (IAV PR/8) 
was harvested 40h post-inoculation from the allantoic fluid of 10 day old embryonated 
eggs and purified through a 35% sucrose cushion. Virus was inactivated with UV light 
(254nm at 6-inch distance) for 40min as previously described192. Inactivated virus was 
disrupted by freezing on dry ice and ethanol, thawing at 37°C, and vortexing for 1min. 
The freeze thawing cycle was repeated three times. Inactivation was confirmed by the 
inability of the virus to replicate in MDCK cells (Madin-Darby canine kidney cells, gift 
from Dr. Scott Hensley, University of Pennsylvania) in the presence of 2mg/ml trypsin. 
DDO is a single stranded 268nt in vitro-transcribed RNA that contains the 
immunostimulatory motif of a DVG and was previously characterized169. DDO was 
produced, stored, characterized, and quality controlled as described169,192. 
3.3.4 Mouse immunization and injections 
For immunization, mice were anesthetized with isoflurane and injected 
subcutaneously(s.c.) into the rear footpad with 10µg disIAV vaccine diluted in PBS 
adjuvanted with 5µg DDO, 5µg Low Molecular Weight polyinosine-polycytidylic acid 
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(poly I:C, InvivoGen), or Alum (Alhydrogel 2%, InvivoGen) at 50% v/v at final volume of 
30µl per dose manufacturer recommendations. Mice were primed and boosted 14 days 
later with the same vaccine formulation.  For adjuvant only experiments, mice were 
anesthetized with isoflurane and injected s.c. into the rear footpad with PBS, 5µg DDO, 
or 5µg poly I:C diluted with PBS to a final volume of 30µl.  
3.3.5 RT-qPCR from footpads and lymph nodes 
The flesh of injected foot pads and draining lymph nodes were harvested at 4, 
12, or 24h post-injection and placed in TRIzol (Invitrogen). Two lymph nodes were 
pooled to increase RNA yield and quality. One microgram of RNA isolated by TRIzol was 
reversed transcribed using high capacity RNA to cDNA reagents (Applied Biosystem). 
qPCR assays were performed using SYBR Green PCR Master Mix (Applied Biosystem) 
in a Viia7 Applied Biosystem Lightcycler. Primers used in the assay were: 
Β actin for-5’-AGGTGACAGCATTGCTTCTG-3’ and rev-5’ 
GCTGCCTCAACACCTCAAC-3’, Ifnb1 for-5’- AGATGTCCTCAACTGCTCTC-3’ and rev-
5’- AGATTCACTACCAGTCCCAG-3’, Mx1 for-5’- CAACTGGAATCCTCCTGGAA-3’ and 
rev-5’- GGCTCTCCTCAGAGGTATCA’3’,  Ccl5 for-5’- GCAGCAAGTGCTCCAATCTT-3’ 
and rev-5’- CAGGGAAGCGTATACAGGGT-3’,  Il6 for-5’- 
ACAGAAGGAGTGGCTAAGGA-3’ and rev-5’- CGCACTAGGTTTGCCGAGTA-3’,  Il1b 
for-5’- TTGACGGACCCCAAAAGAT-3’ and rev-5’- GATGTGCTGCTGCGAGATT-3’. 
3.3.6 Flow cytometry 
Single-cell suspensions of spleen and popliteal lymph node were prepared and 
stained with fluorochrome-labeled antibodies as previously described185. Popliteal lymph 
nodes used for DC staining were digested using DNase (1µg/ml) and Liberase (5µg/ml) 
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in Roswell Park Memorial Institute (RPMI) 1640 Medium (Life Technologies) for 20min at 
37°C. Fixable Viability Dye eFluor506, monoclonal antibody specific for mouse, Ly6c 
(clone HK1.4), CD3 (clone 17A2), CD19 (clone eBio1D3), B220 (clone RA3-6B2), NK1.1 
(clone PK136), and CD11b (clone M1/70)) were obtained from eBioscience. Monoclonal 
antibodies specific for mouse CD3 (clone 17A2), CD4 (clone GK1.5), CD11a (clone 
H11578), XCR1 (clone ZET), PDCA1 (clone 129cl), CD11c (clone N418), SIRPα (clone 
P84), CD64 (clone x54/7.1) and MHC-II (clone M5/114.15.2) were obtained from 
Biolegend. Monoclonal antibodies specific for mouse CD86 (clone GL1) and CD8 (clone 
53-6.7) were obtained from BD BioSciences. IAV-specific tetramers:  H-2Db tetramers 
bearing NP336-374 (ASNENMETM) and I-Ab tetramers bearing NP311-325 
(QVYSLIRPNENPAHK) were obtained from NIH Tetramer Core Facility at Emory 
University. Samples were acquired on a LSRFortessa (BD Bioscience) cytometer and 
analyzed using the FlowJo Software (TreeStar). 
3.3.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 8 for Mac (GraphPad 
Software). RT-qPCR and flow cytometry data were analyzed by two-way ANOVA 
followed by Tukey’s multiple comparison test.  
3.4 Results 
3.4.1 Subcutaneous injection of a DDO-adjuvanted vaccine induces CD8+ T-cell 
responses   
We previously showed that upon intramuscular immunization DDO induces a 
robust type 1 immune response in mice that included antigen-specific IgG2c antibodies, 
TNFα- and IFNɣ-producing CD4+ T-cells, and CD8+ T-cells192. To confirm that DDO is 
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effective in generating antigen-specific CD8+ T-cells when used during subcutaneous 
(s.c.) immunization, and to compare its activity with the gold standard RNA adjuvant 
dsRNA mimic polyinosine-polycytidylic acid (poly I:C), we used a model of disrupted 
influenza A virus (disIAV) vaccination. Mice were immunized twice, 14 days apart, with 
disIAV alone or adjuvanted with DDO, low molecular weight poly I:C, or the type 2 
immunity-inducing adjuvant alum. To assess the T-cell response, spleens were 
harvested 7 days post-boost and antigen-specific T-cells were examined using IAV-
specific tetramer staining. DDO induced greater antigen-specific CD8+ T-cell responses 
by both number and percentage than all other groups, including those immunized in the 
presence of poly I:C. Mice immunized with alum-adjuvanted vaccines completely failed 
to induce CD8+ T-cell responses, as expected (Fig 3.1).  
3.4.2 DDO induces robust cDC1 accumulation in the draining lymph node 
DCs are critical translators of the innate immune response into adaptive 
immunity153. DCs recruited to the draining lymph node at the time of T-cell priming direct 
and determine the adaptive immune response bias towards type 1 or type 2 immunity61. 
DCs are divided into three main subtypes, each with different functions. Type 1 
conventional DCs (cDC1s) are specially equipped to take inert antigen, such as that 
found during killed or subunit vaccination, and cross-present to activate CD8+ T-cells61. 
In contrast, cDC2s more readily activate CD4+ T-cells152. Finally, plasmacytoid DCs 
(pDCs) express high levels of virus sensors and are specially equipped to produce type I 
interferon (IFN) upon sensing viral nucleic acid but are not typically thought as activators 
of naïve T-cells156.  
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To examine the timing of DC recruitment to the draining lymph node and the 
changes that occurred in the DC composition of the draining lymph node upon s.c. 
injection, mice were injected with PBS, DDO, or poly I:C,  and draining lymph nodes 
were harvested 12, 24, or 36h post-injection. At baseline, the conventional DC 
population composition in the lymph node is about 60% cDC2 (XCR1-, SIRPα+) and 40% 
cDC1 (XCR1+, SIRPα-) (Figure 3.2A, C). Both DDO and poly I:C injection increased the 
percentage and number of cDC1s in the lymph node which peaked at 12h post-injection 
(Figure 3.2A-B). cDC2s were reduced by percentage in the lymph node due to the early 
influx of cDC1s, with a maximal reduction in percentage at 12h post-injection (Figure 
3.2C-D). The composition of the cDCs within the lymph node returned to baseline 
percentages by 36h post-injection, as shown by the ratio of cDC1 to cDC2 returning to 
the level of PBS (Figure 3.2E). In addition, we observed that the number and percentage 
of pDCs (B220+, PDCA1+) were increased in the lymph node reaching a maximin at 
24hpi upon injection of both DDO and poly I:C (Figure 3.2F-G).  Overall, s.c. injection of 
DDO induces robust and rapid accumulation of cDC1s and pDCs in the draining lymph 
node, similar to poly I:C.  
3.4.3 cDC1s are required for DDO-induced CD8+T-cell responses 
cDC1s are excellent at cross-presenting antigen and are therefore important for 
the generation of CD8+ T-cell responses to subunit and killed vaccines61. Development 
of cDC1s, but not cDC2s or pDCs, depends on the transcription factor BATF3146. We 
first investigated the requirement for BATF3 in cDC1 accumulation in the draining lymph 
node after DDO injection. Mice lacking BATF3 (Batf3-/-) and WT mice were injected as 
described above and analysis of the composition of DCs in the lymph node 12h after-
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injection confirmed that BATF3 is required for cDC1 accumulation, but not for cDC2 or 
pDCs (Figure 3.3A-C). To assess the role of cDC1s in the induction of antigen-specific 
CD8+ T-cells responses to DDO-adjuvanted vaccines, mice lacking BATF3 and WT 
mice were vaccinated against IAV as described above.  Spleens were harvested 7d 
post-boost for T-cell analysis. Antigen-specific CD8+ T-cells were only generated in 
response to DDO-adjuvanted vaccines in WT mice, but not in Batf3-/- mice lacking 
cDC1s (Figure 3.3D). Overall, these data show that DDO injection induced a cDC1 
response that is required for antigen-specific CD8+ T-cell responses.  
3.4.4 DDO induces a local IFN response 
To investigate the early response to DDO injection leading to the accumulation of  
cDC1s in the draining lymph node, mice were injected s.c. with PBS, DDO, or poly I:C 
and the injected footpad and draining lymph node were harvested at 4, 12, and 24h 
post-injection for cytokine expression analysis by RT-qPCR. At 4h post-injection, Ifnb1 
transcripts peaked in the footpad and quickly returned to near baseline levels for both 
DDO and poly I:C (Figure 3.4A). Transcription of IFN-stimulated genes (ISGs), such as 
Mx1 and the chemokine Ccl5 peaked at 12h post-injection for both DDO and poly I:C 
(Figure 3.4B-C). Mx1 returned to baseline expression levels by 24h but Ccl5 remained 
elevated. Both DDO and poly I:C induced transient Il6 expression at 4h post-injection 
(Figure 3.4D). Interestingly, DDO induced greater Il1b expression than poly I:C in the 
injection site, indicating differences in the inflammatory response between these RNA 
molecules (Figure 3.4E).  
In the draining lymph node, greater differences in response to treatments were 
revealed. Only injection with poly I:C resulted in detectable Ifnb1 transcripts in the 
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draining lymph node at any time point (Figure 3.4F). Both DDO and poly I:C injection 
induced ISG transcription at 4h in the draining lymph node, however, poly I:C induced 
sustained ISG expression that lasted at least 12h post-injection (Figure 3.4G-H). These 
data support the induction of systemic type I IFN responses by poly I:C, a response not 
observed in DDO-injected mice. Inflammatory cytokines Il6 and Il1b were not 
significantly induced over PBS injected mice in either condition, indicating a primarily 
local inflammatory response at these time points (Figure 3.4I-J).  
In both the footpad and the lymph node, other type I IFN gene transcripts were 
examined including Ifna1, Ifna2, Ifna4, Ifna5, Ifna6, Ifna12, Ifna13, and type III IFN or 
IL28a. None of the examined gene transcripts showed any elevation above PBS in any 
tissue or timepoint examined. As Ifnb1 transcript copy numbers were the only interferon 
copy numbers that were elevated upon DDO injection, we determined that IFNβ was the 
primary IFN produced at the site of injection.  
Together, these data show that DDO induces a local type I IFN response, in 
contrast to poly I:C, a known inducer of systemic type I IFN responses193. In addition to 
the magnitude of IFN responses, DDO induced a stronger expression of inflammatory 
cytokines than poly I:C. These data underscore the differences between the local 
responses to two seemingly similar RNAs, one a natural virus-derived pathogen 
molecular pattern (PAMP) and one a synthetic dsRNA, confirming previous observations 




3.4.5 Type I IFN is required to initiate immune responses to DDO-adjuvanted vaccines 
Type I IFN is a cytokine family with broad functions that include preparing cells 
for a viral challenge and helping shape the adaptive immune response. Type I IFN can 
aid in the activation of DCs108,110 and lead to the activation and type 1 immunity 
polarization of T-cells117,118. As we have observed a role for type I IFN in inducing T-cell 
responses upon i.m. immunization with DDO-adjuvanted vaccines, we next tested if type 
I IFN was necessary for cDC1 accumulation in the lymph node upon s.c. immunization. 
WT mice and mice deficient in type I IFN signaling (Ifnar-/-) were injected in the footpad 
with PBS or DDO and the draining lymph nodes were harvested at 12h post-injection to 
analyze the DC composition. In contrast to WT mice, upon DDO injection, there was no 
increase in the percentage of cDC1s in the draining lymph node in Ifnar-/- mice (Figure 
3.5A-B) indicating a dependence on type I IFN signaling for the accumulation of cDC1s 
in the draining lymph node. Additionally, there was no increase in the percentage of 
pDCs in the draining lymph nodes of DDO Ifnar-/- mice (Figure 3.5C).  
 To determine if the dependence on type I IFN signaling for DC accumulation 
resulted in a reduction in T-cell responses in this system, mice were vaccinated against 
IAV as described above. Ifnar-/- mice vaccinated with DDO-adjuvanted vaccines were 
unable to generate IAV-specific CD8+ T-cells (Figure 3.5D), indicating a complete 
reliance on type I IFN for response to DDO-adjuvanted vaccines. 
3.4.6 TLR3 is required for the accumulation of DCs in the draining lymph node and the 
subsequent CD8+ T-cell response in response to DDO 
Adjuvants, including DDO and poly I:C, act as PAMPs69. PAMPs are sensed 
through various pattern recognition receptors (PRRs) including endosomal RNA sensors 
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TLR773 and TLR369,70 and cytosolic RNA sensors RIG-I and MDA5 which signal through 
the common adaptor MAVS for the production of type I IFN and other cytokines77–80 . As 
type I IFN is required for both the accumulation of cDC1s in the draining lymph node and 
the adaptive immune response induced by DDO, we chose to examine how DDO is 
sensed upon s.c injection. 
To investigate which of these sensors are responsible for the recognition of DDO 
and its immunostimulatory activity, WT mice and Tlr7-, Tlr3-/-, and Mavs-/- mice were 
injected with PBS or DDO and DC composition in the lymph node was evaluated at 12h 
post-injection. WT and Mavs-/- mice had similar changes in the DC composition after 
injection with DDO (Figure 3.6A-C). Similar to the response in Mavs-/- mice, the DC 
composition in the lymph nodes of DDO-injected Tlr7- mice mirrored the response of WT 
mice (Figure 3.6D-F). However, injection of Tlr3-/- mice, resulted in a loss of the cDC 
response in DDO-injected mice compared to WT mice (Figure 3.6G-H). The pDC 
response remained intact in Tlr3-/- upon DDO injection (Figure 3.6I), likely due to the low 
expression level of TLR3 by pDCs. These data illustrate the critical role TLR3 plays in 
sensing DDO to lead to the accumulation of cDC1s in the draining lymph node.  
As all conditions that abrogated cDC1 responses also eliminated T-cell 
responses to DDO-adjuvanted vaccines, we next examined the role of TLR3 during T-
cell responses upon DDO-adjuvanted vaccinations. WT and Tlr3-/- were vaccinated as 
above. In concordance with Ifnar-/- and Batf3-/- studies, the loss of TLR3 and subsequent 
loss of cDC1 skewing in the lymph node resulted in a reduction of the antigen-specific 
CD8+ T-cell response (Figure 3.6J). These data demonstrate a critical role for TLR3 in 




Understanding the innate immune response needed to instruct a CD8+ T-cell 
response to vaccination is critical for targeted vaccine design. DDO is a 268nt RNA 
derived from the primary immunostimulatory molecule of SeV infections169,170. Here we 
show that DDO induces a local type I IFN and inflammatory response that leads to the 
accumulation of cDC1s in the draining lymph node. cDC1 recruitment to the lymph node 
relies on TLR3 and type I IFN signaling and loss of cDC1 accumulation in the draining 
lymph nodes prevents the development of antigen-specific CD8+ T-cell responses. 
 TLR3 is a known poly I:C sensor69 and we show here that is also required for 
DDO-induced immune responses during vaccination in mice. However, the cytokine 
response to these PAMPs is not identical. DDO does not induce a systemic type I IFN 
response and triggers higher expression of Il1b than poly I:C. These intriguing results 
raise questions about how these differences arise and whether additional sensors or cell 
types are engaged by DDO at the injection site. Studies with licensed adjuvants, alum 
and MF59, have shown that additional innate cells such as natural killer cells and 
monocytes are critical for antigen transport to the lymph node194. Perhaps DDO and poly 
I:C interact with different cells to induce this differential cytokine response. Further 
examination of the exact cell types interacting with DDO is needed to fully understand its 
adjuvancy.  
 Another group using a full-length version of the SeV DVG (546nt) as a vaccine 
adjuvant showed that its ability to induce type I IFN and protect from lethal challenge 
upon i.m. injection is dependent on RIG-I182. We show that DDO, which is a truncated 
version of the full length DVG169, induced cDC1 accumulation in the draining lymph node 
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and antigen specific CD8+T cells in a TLR3-dependent manner, despite that DDO is 
sensed through RIG-I when transfected into cells, similarly to the full length DVG169. It 
possible that differences in the concentration of DDO used, DDO size, route of 
immunization, or time point analyzed explain these seemly contradictory results.  
Intriguingly, in order to trigger RIG-I, DDO would have to be internalized to the 
cytoplasm after s.c. injection. Work from the Mossman lab has demonstrated the need 
for class-A scavenger receptors for the internalization and subsequent sensing of 
dsRNA through both TLR3 and RLRs195,196. Additionally, proteins such as SIDT2 have 
been identified as RNA transporters from endosomes into the cytosol for RLR 
sensing197. Further studies are required to determine if class-A scavenger receptors or 
SIDT2 are used by DDO and if differences between the full-length DVG-adjuvanted 
vaccinations and DDO-adjuvanted vaccinations change how these RNA interact with 
proteins involved with RNA internalization.  
 Our data show that DDO completely relies on cDC1s to induce CD8+ T-cell 
responses. Any loss of cDC1 accumulation in the draining lymph node, through loss of 
BATF3, type I IFN signaling, or TLR3, abrogated DDO’s adjuvancy. It is clear that cDC1s 
are a potent driver of CD8+ T-cell responses in this system and many viral infections, 
including West Nile virus146, cytomegalovirus147, influenza virus148, cowpox virus149, and 
others. However, the exact mechanism of cDC1 activation and PAMP sensing during 
many vaccinations is still unclear. Studies from the Kedl lab indicate the IFN-stimulated 
gene IL-27 production from cDC1s as an indicator of subsequent CD8+ T-cell responses 
after subunit vaccination115,116, however they did not examine the signals that lead to the 
activation of and IL-27 production by cDC1s. To gain a comprehensive picture of how 
75 
 
CD8+ T-cell responses are induced, we must fully understand how the cells directly 
instructing CD8+ T-cells are activated. 
 We have shown DDO act as a type 1 immunity inducing adjuvant using an 
influenza vaccination model192. DDO are derived from a different virus than they are 
used to vaccinate against and is likely that DDO would be beneficial in vaccines for other 
intracellular pathogens. Intracellular parasites remain a difficult target for vaccination and 
pathogens such as plasmodium, toxoplasma, and leishmania rely on type 1 immune 
responses for their clearance and control198–200. For effective immunizations to occur, the 
proper antigens must be targeted. Recent advances in epitope discovery, such as T-
scan201, are allowing for more targeted vaccine antigen design. By pairing appropriate 
antigens with DDO, tailored vaccinations against diverse pathogens could be tested.  
 Great strides have been made in understanding the difference between 
responses to infection and vaccination with a shift in the focus on the role of innate 
responses. We have shown an adjuvant derived from a natural PAMP is sensed by 
TLR3 and induces cDC1 accumulation in the draining lymph node and that this process 
is necessary for antigen specific CD8+ T cell development. This study has uncovered 
the early innate immune response to DDO and has identified potential targets for type 1 





Figure 3.1. DDO induces a robust CD8+ T-cell response upon IAV immunization. 
WT mice were immunized were immunized twice, 14d apart, with 10µg inactivated and 
disrupted IAV PR/8 (disIAV) alone (--) or adjuvanted with 5µg DDO, 5µg poly I:C (pIC), 
or 50% volume Alum. (n=5 mice/group). A-B Spleens were harvested 7d post-boost and 
processed into a single cell suspension and examined by flow cytometry. Mean±SEM of 
each group is shown. Tetramer+ CD8+ T-cells were defined as live, CD3+, CD8+CD4-, 
tetramer+. A Percent of CD8+ T-cells that are tetramer+. (n=4-5 mice/group) B total 
number of antigen specific CD8+ T-cells in the spleen. *=p<0.05, **=p<0.01. Data 





Figure 3.2. DDO induces accumulation of cDC1s in the draining lymph node.  WT 
mice were injected s.c. with PBS, 5µg DDO, or 5µg poly I:C in the rear footpad. Draining 
lymph node were collected 12, 24, or 36h post-injection for analysis. PBS injected mice 
were harvested 24h post-injection. (n= 6/group). Mean±SEM of each group is shown (A-
G). A-B cDC1 were characterized as Live, CD3-NK1.1-B220-CD19-, MHCIIhi, CD64-
,Ly6c-, CD11chi, XCR1+SIRPa-. A Percent of conventional DCs that are cDC1s. B 
Number of cDC1s in the draining lymph node at 12h post-injection. C-D cDC2 were 
characterized as Live, CD3-NK1.1-B220-CD19-, MHCIIhi, CD64-,Ly6c-, CD11chi, XCR1-
SIRPa+. C Percent of conventional DCs that are cDC2s. D Number of cDC2s in the 
draining lymph node at 12h post-injection. E The ratio of cDC1 to cDC2 was created by 
dividing the number of cDC1 by number of cDC2 at the indicated time post-injection. F-G 
pDCs were characterized as live, PDCA1+B220+. F percent of cells in the lymph node 
that are pDCs. G Number of pDCs in the draining LN. *=p<0.05, **=p<0.01, ***=p<0.001, 
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****=p<0.0001 compared to PBS control. Data represent one representative experiment 






Figure 3.3. DDO requires cDC1s to induce a CD8+ T-cell response. A-C WT (black) 
and Batf3-/- (orange) mice were injected s.c. with PBS, 5µg DDO, or 5µg poly I:C (pIC). 
Draining lymph node were harvested 12h post-injection and analyzed by flow cytometry 
(n=4-6/group). Mean±SEM of each group is shown. A Percent of conventional DCs that 
are cDC1s characterized as  live, CD3-NK1.1-B220-CD19-, MHCIIhi, CD64-,Ly6c-, 
CD11chi, XCR1+SIRPa-B Percent of conventional DCs that are cDC2s characterized as  
live, CD3-NK1.1-B220-CD19-,MHCIIhi, CD64-,Ly6c-, CD11chi, XCR1-SIRPa+. C Percent of 
cells in the LN lymph nodes that are pDCs were characterized as live, PDCA1+B220+. D 
WT and Batf3-/- were immunized twice, 14d apart, with 10µg disIAV alone (--) or 
adjuvanted with 5µg DDO or 5µg pIC.  Spleens were harvested 7d post-boost, 
processed into a single cell suspension, and analyzed by flow cytometry (n=3-4/group). 
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Mean±SEM of each group is shown. D Number of tetramer+ CD8+ T-cells were defined 
as Live, CD3+, CD8+CD4-, tetramer+. **=p<0.01, ***=p<0.001, ****=p<0.0001. Data 





Figure 3.4. DDO activates a rapid type I IFN response with a different cytokine 
profile than poly I:C. WT mice were injected s.c. with PBS, 5µg DDO, or 5µg poly I:C 
(pIC) in the rear footpad. Injected footpads and draining LN were harvested 4, 12, and 
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24h post-injection. A-E Expression of transcripts in the footpad are relative to the 
housekeeping gene β-actin. (n=6/group). Mean±SEM of each group is shown. A 
Relative Ifnb1. B Relative Mx1. C Relative Ccl5. D Relative Il6. E Relative Il1b. F-J Two 
lymph nodes/group were pooled into one sample for better RNA quality. Expression of 
transcripts are relative to the housekeeping gene β-actin. (n=3/group). Data correspond 
to mean±SEM of each group. F Relative Ifnb1. G Relative Mx1. H Relative Ccl5. I 
Relative Il6. J Relative Il1b. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Data 






Figure 3.5. Type I IFN is required for cDC1 accumulation and the subsequent T-cell 
response to DDO-adjuvanted vaccines. WT (black) and Ifnar-/- (red) mice were 
injected s.c. with PBS or 5µg DDO in the rear footpad. Draining lymph nodes were 
harvested 12h post-injection and processed into a single cell suspension for analysis by 
flow cytometry. (n=4-6/group) Mean±SEM of each group is shown. (A-C). A Percent of 
conventional DCs that are cDC1s characterized live, CD3-NK1.1-B220-CD19-, MHCIIhi, 
CD64-,Ly6c-, CD11chi, XCR1+SIRPa-. B Percent of conventional DCs that are cDC2s 
characterized as live, CD3-NK1.1-B220-CD19-, MHCIIhi, CD64-, Ly6c-, CD11chi, XCR1-
SIRPa+. C Percent of cells in the lymph nodes that are pDCs that are characterized as 
live, PDCA1+B220+. D WT and Ifnar-/- mice were immunized twice, 14d apart, with 10µg 
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disIAV alone (--) or adjuvanted with 5µg DDO.  Spleens were harvested 7d post-boost, 
processed into a single cell suspension, and analyzed by flow cytometry (n=3-4/group). 
Mean±SEM of each group is shown. D Number of tetramer+ CD8+ T-cells were defined 
as Live, CD3+, CD8+CD4-, tetramer+. **=p<0.01, ****=p<0.0001. Data represent one 





Figure 3.6. TLR3 is required for cDC1 migration in response to DDO injection.  A-C 
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WT (black) and Mavs-/- (cyan) mice were injected s.c. with PBS or 5µg DDO in the rear 
footpad. Draining lymph nodes were harvested at 12h post-injection, processed into a 
single cell suspension, and analyzed by flow cytometry. (n=4-6/group) Mean±SEM of 
each group is shown.  A Percent of conventional DCs that are cDC1s characterized live, 
CD3-NK1.1-B220-CD19-, MHCIIhi, CD64-, Ly6c-, CD11chi, XCR1+SIRPa-. B Percent of 
conventional DCs that are cDC2s characterized as live, CD3-NK1.1-B220-CD19-,MHCIIhi, 
CD64-,Ly6c-, CD11chi, XCR1-SIRPa+. C Percent of cells in the lymph nodes that are 
pDCs that are characterized as live, PDCA1+B220+. D-F WT (black) and Tlr7- (green) 
mice were injected s.c. with PBS or 5µg DDO in the rear footpad. Draining lymph nodes 
were harvested at 12h post-injection, processed into a single cell suspension, and 
analyzed by flow cytometry. (n=6/group Mean±SEM of each group is shown.  D Percent 
of conventional DCs that are cDC1s characterized as in A. E Percent of conventional 
DCs that are cDC2s characterized as in B. F percent of cells in the lymph nodes that are 
pDCs characterized as in C. G-I WT (black) and Tlr3-/- (blue) mice were injected s.c. with 
PBS or 5µg DDO in the rear footpad. Draining lymph nodes were harvested at 12h post-
injection, processed into a single cell suspension, and analyzed by flow cytometry. (n=2-
4/group) Mean±SEM of each group is shown.  G Percent of conventional DCs that are 
cDC1s characterized as in A. H Percent of conventional DCs that are cDC2s 
characterized as in B. I percent of cells in the lymph node that are pDCs characterized 
as in C. J WT and Tlr3-/- mice were immunized twice, 14d apart, with 10µg disIAV alone 
(--) or adjuvanted with 5µg DDO.  Spleens were harvested 7d post-boost, processed into 
a single cell suspension, and analyzed by flow cytometry (n=3-4/group). Mean±SEM of 
each group is shown. Number of tetramer+ CD8+ T-cells were defined as Live, CD3+, 
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CD8+CD4-, tetramer+. *=p<0.05, **=p<0.01, ****=p<0.0001. Data represent one 
representative experiment out of 2 independent repeats. 
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CHAPTER 4: Discussion 
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4.1 Summary of Findings 
In addition to stimulating the immune response, vaccine adjuvants play the 
important role of shaping the type of adaptive immune responses that are developed. In 
this dissertation, we investigated the type of immune response induced by a virus-
derived vaccine adjuvant, DDO. We hypothesized, based on in vitro type I IFN 
expression in response to DDO transfection and studies using a prototype DDO169,170, 
that DDO would act as a type 1 immunity inducing adjuvant. In addition, we studied the 
innate immune mechanism leading to the adjuvant activity of DDO in mice. 
Chapter 2 describes the adaptive immune response generated during DDO-
adjuvanted influenza A virus vaccination. We found that DDO induces the hallmarks of 
type 1 immunity, including Th1 and CD8+ T-cells, as well as an IgG2c-dominated 
humoral response. Using a heterosubtypic challenge model that primarily depends on 
CD8+ T-cells for protection, we showed that DDO induces effector CD8+ T-cells upon 
vaccination. Although DDO is a potent adjuvant in isolation, we found that DDO can 
synergize with AddaVax (the research version of the adjuvant MF59) to induce an even 
stronger type 1 immune response.  
Chapter 3 defines the early innate immune response to DDO injection that results 
in a CD8+ T-cells response. We found that upon s.c. injection, DDO is sensed through 
the endosomal sensor TLR3, not TLR7 or the cytosolic RLRs and induces a type I IFN 
with an inflammatory cytokine profile distinct from the synthetic viral RNA analog poly 
I:C. Type I IFN signaling was required for cDC1 accumulation in the draining lymph node 
and for a subsequent CD8+ T-cell response. Loss of cDC1 accumulation in the draining 
lymph node completely abrogated the CD8+ T-cell response to DDO-adjuvanted 
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vaccines. Overall, this work contributes to the understanding of innate immunity 
requirements to induce CD8+ T-cell response to killed and subunit vaccines.  
4.2 DVGs in vaccines: old friends, new applications 
4.2.1 DDO as an adjuvant 
In chapters 2 and 3, we describe that DDO induces all the major hallmarks of a 
type 1 immune response, including IgG2c isotype switching, Th1 CD4+ and CD8+ T-
cells. We chose to use IAV as our model pathogen, as many tools exist to study both 
humoral and cellular responses to IAV. However, the full extent of DDO’s adjuvancy has 
yet to be uncovered.  
4.2.2 DVGs in vaccines 
The DDO used in this study was derived from the highly immunostimulatory DVG 
found in SeV infections. Before the role of DVGs as immunostimulatory molecules was 
understood, they were used in vaccines, unbeknownst to the creators of the vaccines. 
Most notably, the measles virus (MV) vaccine, one of the most successful vaccines, 
contains DVGs in the viral stocks used to grow the vaccine202. Interestingly, the 
Edmonston-Zagreb vaccine strain produced the most DVGs in culture, and was also the 
most successful at seroconverting young infants compared to other strains203. The MV 
vaccine stocks more readily induce type I IFN than wild-type strains of the virus and the 
IFN induction is associated with the presence of cbDVGs in vitro204. Together, these data 
support the immunostimulatory effect of DVGs in vaccination and point to their role as a 
naturally occurring adjuvant in measles vaccines. In addition to MV vaccines, oral polio 
virus vaccine stocks were found to contain DVGs, however the role of these DVGs and 
their immunostimulatory capabilities has yet to be defined164. 
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Large quantities of DVGs were also identified in stocks of the live seasonal 
influenza vaccine166. The influenza live vaccine relies on viral replication to induce 
immune responses and was removed from use due to poor immunogenicity166. A known 
DVG function is interference with standard genome replication162,205, therefore, the 
authors hypothesized that these DVGs hampered viral replication upon vaccination and 
prevented the induction of an immune response. It is important to note that influenza 
viruses predominately produce deletion DVGs, which are typically less 
immunostimulatory than their copy-back counterparts205. While the authors discover the 
presence of DVGs, no experiments were done to directly support their hypothesis of 
DVGs interfering with replication. Further work needs to be done to characterize the 
influenza DVGs in live vaccines; however, this study highlights that DVGs in vaccines 
are not all created equal.  
When growing viral stocks for vaccination, DVGs must be carefully considered 
and evaluated. Deletion DVGs, like those found in the live influenza vaccine, are likely 
going to be detrimental to vaccine efficacy as they primarily interfere with virus 
replication and nullify the benefits of using an attenuated pathogen. In contrast, cbDVGs, 
such as those found in MV vaccine stocks, are highly immunostimulatory 204,206. cbDVGs 
may act as natural adjuvants in these vaccines, allowing for initiation of innate immune 
responses and subsequent sterilizing immunity. However, levels of cbDVGs must be 
examined. Too many cbDVGs may result in a shutdown of viral replication and loss of 
immunity induction205. Therefore, it is critical to grow viral vaccine stocks in a way that 
limits but does not eliminate cbDVGs. Further examination of attenuated virus vaccine 
stocks may uncover additional vaccines containing DVGs due to their near ubiquitous 
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presence in viral infections205, however their immunomodulatory capabilities and impact 
on the vaccine efficacy will need to be carefully determined. There is no simple answer 
to whether DVGs in vaccine stocks are beneficial; careful examination of how vaccine 
stocks are grown as well as the type of DVG produced are important for understanding 
attenuated vaccine efficacy. 
4.2.3 Synthetic DVGs in vaccines 
Once the immunostimulatory capabilities of DVGs were discovered, they were 
quickly sought after as vaccine adjuvants and antivirals. Work from other groups with the 
full-length in vitro transcribed (IVT) SeV cbDVG-546 as an adjuvant for an IAV vaccine, 
found that RIG-I was essential for protection from weight loss upon lethal challenge after 
vaccination182. Interestingly, cbDVG-546, from which DDO is derived, was sensed by a 
different PRR than DDO in their system. Their IVT cbDVG was almost twice as large as 
our DDO, pointing to a potential role for RNA size in internalization and subsequent 
sensing of dsRNA through cytosolic sensors.  
Studies from the Mossman lab have identified class-A scavenger receptors (SR-
A) as critical proteins for dsRNA internalization and cytosolic sensing195,196. These 
studies were done using poly I:C as a dsRNA mimic and found that SR-A was important 
for both cytosolic RLR sensing and endosomal TLR3 sensing195. While SR-A were 
important for bringing RNA into the endosome for subsequent sensing, they were not the 
RNA transporter required to move the RNA from the endosome into the cytosol. 
Additional studies identified the protein SID1 transmembrane family member 2 (SIDT2) 
as a transporter of RNA, including poly I:C, from endosomes into the cytosol for RLR 
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sensing197. Poly I:C is not a uniform PAMP but is instead a collection of dsRNA of 
varying lengths.  
Perhaps the length of the dsRNA is important for determining its fate within the 
endosome, shorter RNAs, such as DDO would be left in the endosome to interact with 
TLR3, while larger RNAs, such as cbDVG-546 would interact with RNA transporters and 
become internalized for RLR sensing. Further studies into the involvement of RNA 
length for internalization and the exact proteins involved could result in the development 
of DDO adjuvants that are engineered for sensing by specific PRRs, simply by varying 
their length and broaden their potential use in vaccines. 
4.2.4 Broader use of DDO adjuvants 
DVG adjuvants have been primarily studied in vaccines against viral pathogens. 
However, viruses are unique as intracellular pathogens. Intracellular parasites such as 
plasmodium, toxoplasma, and leishmania rely on type 1 immune responses for their 
clearance and control198–200. While DDO are virus-derived, the hallmarks of the immune 
response generated by this adjuvant could be of use against a broader spectrum of 
pathogens. DDO are derived from SeV and induce protective immunity against IAV, 
therefore we can predict that DDO induce broadly applicable type 1 immune responses. 
Adjuvants stimulate an innate immune response and therefore induce a response 
towards pathogen categories, not specific pathogens. Innate responses to intracellular 
pathogens, such as those induced by DDO, converge in the cytokines they induce to 
shape adaptive immune responses142. Thus, by taking an innate immunostimulatory 
molecule such as DDO and pairing it with antigens from other pathogens, the non-
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specific innate immune response can instruct the antigen-specific adaptive immune 
response towards type 1 immunity.  
For example, Leishmania parasites require Th1 cells for their control199, we have 
shown that DDO induces the activation of Th1 cells upon vaccination. A combination of 
the immunodominant peptide PEPCK207 with DDO could be used to explore the DDO’s 
ability to induce functional protective Th1 responses. Furthermore, recent advances in 
antigen screening capabilities such as T-Scan201 are allowing for epitope discovery and 
antigen development for vaccination. These discoveries have paved the way for targeted 
vaccine design—correct pairing of adjuvants, such as DDO, with immunodominant 
antigens could lead to more tailored immune responses to vaccination.  
4.3 Combination adjuvants: the sum is greater than the parts 
4.3.1 DDO as a combination adjuvant 
In chapter 2, we demonstrate that DDO synergizes with AddaVax, a mixed type 
1/ type 2 immunity inducing adjuvant, to induce robust type 1 immunity. During subunit 
vaccination, we show that DDO+AddaVax induce robust IgG2c responses, which are 
absent during vaccination with either individual adjuvant. Additionally, DDO+AddaVax-
adjuvanted killed IAV vaccines induce greater Th1 responses than DDO or AddaVax-
adjuvanted vaccinations. Interestingly, DDO+AddaVax reduce the recovery time from 
heterosubtypic challenge compared to DDO, while AddaVax alone does not protect from 
heterosubtypic challenge. The data also showed that DDO alone does not require type I 
IFN for recovery from heterosubtypic challenge, loss of IFN signaling resulted in a 
reduction of protection for DDO+AddaVax groups, hinting at a differential mechanism of 
action between DDO alone and DDO+AddaVax.  
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Further examination into the cell types that interact with the adjuvants alone or in 
combination will be critical to tease apart the method of synergy. Injection of DDO alone 
results in a rapid accumulation of cDC1s in the draining lymph nodes of mice. 
DDO+AddaVax likely results in a similar accumulation based on the rapid recovery from 
heterosubtypic challenge in these mice, although additional cell types may be involved, 
including monocytes that are known to accumulate and facilitate antigen delivery in 
response to AddaVax injection194. Additionally, it is not clear whether DDO and AddaVax 
are interacting with the same cells but as AddaVax is an emulsion we predict AddaVax 
packages DDO and antigen together for more efficient delivery into cells. Simultaneous 
in vivo visualization of labeled antigen and adjuvants could be used to test this 
hypothesis and reveal which cells interact with and take up vaccine components upon 
injection. 
Understanding the immunostimulatory mechanism of combined adjuvants and 
their individual components may aid in predicting productive adjuvant synergy. 
Combination adjuvants may work together to deliver antigen to different cell type than 
individual components, as we hypothesize for DDO+AddaVax. Combination adjuvants 
may also result in the engagement of different PRRs either due to delivery to different 
compartments within a cell or interaction with different cell types than the separate 
adjuvants. These differences can lead to differential cytokine expression, and therefore 
trigger different types of adaptive immunity. By studying successful combination 
adjuvants, we can gain insights into how immune responses to adjuvants are generated. 
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4.3.2 Lessons learned from combination adjuvants 
Combination adjuvants have been highly successful in the clinic. The Adjuvant 
System is a set of combination adjuvants that have been used in multiple licensed 
vaccines. One of the Adjuvant System adjuvants is AS01, which is currently in Shingrix, 
a subunit Zoster vaccine protecting against shingles101. AS01 produces robust Th1 
responses and depends on synergy between its components for its adjuvanticity. AS01 
is a liposome based adjuvant that contains 3-O-desacyl-4ʹ-monophosphoryl lipid A 
(MPL) and the saponin QS-2156. MPL is a detoxified derivative of the bacterial 
polysaccharide LPS and is sensed through TLR4208. In mice, MPL is sensed directly by 
APCs and leads to the secretion of IFNɣ by T-cells and isotype switching to IgG2a/c178. 
QS-21 is derived from the 21st fraction of the extract from the bark of the South American 
tree Quillaja saponaria Molina. QS-21 boosts antibody responses and increases CD8+ 
T-cell responses in non-human primates209,210, however the exact mechanism of action 
of QS-21 is not well understood. In vitro studies suggest that QS-21 activated the ASC-
NLRP3 inflammasome211, however it is unknown whether this pathway is utilized in vivo. 
The two adjuvants in AS01 synergize to induce transcriptional pathways not induced by 
either component separately, leading to a drastic increase in IFNɣ producing cells in the 
draining lymph node early after injection and greater cellular responses57. However, the 
exact mechanism of this synergy is still unknown.  
AS03 and AS04 are combination adjuvants that show variable synergy between 
individual adjuvant components. AS03 is an oil-in-water emulsion with α-tocopherol 
(Vitamin E) and is currently in vaccine stocks to prevent potential H5 pandemic 
influenza. AS04 is MPL absorbed onto alum salts and is currently licensed for use in a 
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human papilloma virus vaccine. AS03 induces a robust antibody response and mixed 
Th1 and Th2 response in mice212. While the exact mechanism of adjuvancy by AS03 is 
still under investigation, the components of the adjuvant system appear to synergize to 
induce immunity212. In contrast, the components of AS04 do not synergize but simply 
have an additive effect resulting in enhanced cytokine production and antigen loading by 
APCs213. These studies illustrate that combination adjuvants do not always induce 
synergistic effects; however, they represent important tools for further boosting immune 
responses over the response to individual adjuvants.  
Studies into the mechanism of the Adjuvant System adjuvants give us some 
clues as to what leads to adjuvant synergy. The most successful synergy adjuvants 
include emulsions, similar to what we have seen with DDO and AddaVax synergy. Both 
components of the synergizing adjuvants have some overlap in the type of immune 
response they induce. In contrast, the two components of AS04, alum and MPL, induce 
conflicting types of immune responses. By pairing DDO with an emulsion that induced 
mixed type 1 and type 2 immune responses, DDO was likely able to further boost the 
type 1 immunity inducing aspect of AddaVax.  
In addition to emulsions such as MF59 (AddaVax) and AS03, adjuvants including 
nanoparticles and liposomes are promising components for combination adjuvant 
strategy. One such experimental adjuvant, ISCOMATRIX adjuvant, is a negatively 
charged cage of phospholipid, cholesterol, and saponin. Charged adjuvants allow for 
ionic interactions between antigen and adjuvant or multiple adjuvants. ISCOMATRIX 
alone induces IgG2a and Th1 responses in mice, however the addition of the positively 
charged type 1 immunity-inducing experimental adjuvant Chitosan190 resulted in reduced 
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responses to IAV vaccination in mice214. Chitosan indirectly activates the cGAS-STING 
pathway by stimulating the release of mitochondrial DNA190. Perhaps by combining 
chitosan with ISCOMATRIX, chitosan entered cells differently and was no longer able to 
activate the cGAS-STING pathway preventing its adjuvancy. These data underscore the 
intricacies of adjuvant development, and that adding adjuvants does not necessarily 
result in boosted responses to vaccination.  
4.3.3 Further use of DDO in combination adjuvants 
To fully determine the scope of DDO adjuvancy, DDO could be combined with 
other adjuvants. Ideally, any adjuvant that DDO is paired with should not carry a 
negative charge as RNA is also negatively charged and would repel the adjuvant. For 
synergy to occur, DDO should be paired with other adjuvants that induce some aspects 
of type 1 immunity, such as Th1 cells. DDO induces CD8+ T cell responses, but by 
pairing it with another adjuvant, the CTL response could be further boosted. Emulsions 
show the greatest promise as synergizing adjuvants, and further examination into the 
mechanism of adjuvancy of emulsions could highlight key factors for adjuvant synergy. 
DDO must also be able to interact with an appropriate sensor, if the adjuvant it is paired 
with prevents these interactions, DDO’s adjuvancy will be lost.  
Additionally, vaccination route must be carefully considered when combining 
adjuvants. The studies discussed in this dissertation were carried out using 
intramuscular and subcutaneous injections. In pilot studies, DDO was delivered 
intranasally to mice with no observed adverse effects. Adjuvants such as AddaVax are 
not suited for intranasal delivery, and therefore other adjuvants would need to be 
combined with DDO for intranasal delivery. Both adjuvants must be suitable for the 
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vaccination route and a change in mechanism must be anticipated when changing the 
vaccination route. For example, cyclic dinucleotide adjuvants induce different immune 
responses based on how they are administered215, likely due to the differential cell 
landscape between mucosal and other traditional vaccination routes.  
It is now clear that when it comes to vaccination, the sum is truly greater than the 
parts. Understanding the mechanism of synergy between adjuvants is critical for new 
adjuvant development. For many adjuvants, the mechanism by which they induce 
immune responses is still unclear and that has greatly delayed targeted adjuvant design. 
The additional factor of synergy and predicting if two adjuvants will complement each 
other further complicates vaccine design. Studies illuminating the exact mechanism of 
combination adjuvants and their components, including which cells they interact with, 
what PRRs are engaged, and the primary cytokine response, will allow for better 
predictions of vaccine adjuvant efficacy and tailored vaccine design.  
4.4 PAMPs as adjuvants: tools for understanding immune responses 
4.4.1 DDO as a PAMP adjuvant 
In chapter 3, we determine that DDO relies on TLR3 for the accumulation of 
cDC1s in the draining lymph node and subsequent CD8+ T-cell responses. Murine 
cDC1s express high amounts of TLR361, indicating that cDC1s may directly sense DDO. 
However, differences in expression of Il1β and Ifnb1 upon injection of poly I:C and DDO 
indicate that DDO may be using a second sensor we have not screened for or there may 
also be a difference in signal strength between poly I:C and DDO responsible for this 
differential response. Perhaps other sensors are used in the injection site that lead to the 
recruitment of APCs and these other sensors are responsible for the Il1β induction. 
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Additionally, loss of MAVS or TLR7 could have resulted in a change in the early cytokine 
response but still allowed for cDC1 accumulation in the draining lymph node.  
To fully understand the critical activation of cDC1s in response to DDO we must 
further tease apart the role of TLR3 signaling. TLR3 is required for cDC1 accumulation in 
the draining lymph node and subsequent CD8+ T-cell activation. All studies conducted 
used full body knockouts of TLR3. To determine if TLR3 engagement on DCs is required 
for DDO activity, cell type specific knockouts would need to be generated. A common 
tool for generating cell type specific knock out mice is the Cre-Lox system, however, 
Tlr3fl/fl mice have yet not been generated. Ideally, these mice could be crossed with 
XCR1-Cre mice to conditionally knock out TLR3 on cDC1s and test to see if cDC1s 
directly sense DDO or if other cells are involved. Because cDC1s express high levels of 
TLR366,67, we predict that DDO is directly sensed by cDC1s and TLR3 engagement is 
required for their activation in this system. However, other cells at the injection site may 
also directly sense DDO and lead to chemokine expression to recruit DCs. Ifnb1 is 
rapidly induced in the footpad which implies that DDO is quickly sensed by a PRR. 
Studies examining the cytokine response in the footpad of Tlr3-/-, Mavs-/-, and Tlr7- mice 
would shed light onto the initial response to DDO and its requirement for TLR3 or point 
to a potential role for other sensors in the injection site.  
Our studies primarily focused on examining the CD8+ T-cell response and further 
work must be done to understand the impact TLR3 engagement has on humoral 
responses. We predict that TLR3 is required for humoral responses to DDO-adjuvants, 
even if this requirement is indirect. TLR3 appears to be critical for the initiation of the 
innate immune response to DDO and without these early events, no aspect of adaptive 
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immunity would occur, including antibody responses. Additionally, it is becoming clear 
that B cells require direct PAMP sensing for productive Tfh-B cell communication 
resulting in IgG2a/c isotype switching126,127. Much of the work done investigating IgG2a/c 
isotype switching was done using CpG and examining the role of TLR9 expression on B 
cells125,127, however, similar downstream signaling results from other nucleic acid 
sensing TLRs. Both TLR3 and TLR7 are expressed in B cells66, perhaps DDO is directly 
sensed by B cells to lead to the IgG2c response. Pilot studies in mice deficient for 
MyD88, the adaptor for TLR7 signaling, showed defects in the humoral response to 
DDO-adjuvanted i.m. vaccinations. MyD88 is also the adaptor for IL-1 family cytokine 
signaling which complicates the interpretation of these results. These findings require 
further investigation to determine the role MyD88 and TLR7 in humoral responses. 
Studies examining the humoral response in the presence and absence of TLR3 and 
TLR7 on B cells would be critical to understand the role of direct DDO-sensing by B cells 
for DDO’s adjuvancy.  
Additionally, type I IFN signaling is crucial to generate type 1 immune responses 
to DDO-adjuvanted vaccines, however the exact mechanism of IFNAR-dependence is 
not known. Loss of IFNAR results in a loss of cDC1 accumulation in the draining lymph 
node, T-cell responses, and IgG2c responses. IFN sensing could be required at the site 
of injection, where Ifnb1 is produced, or IFNAR could be required to fully activate DCs, 
as seen with poly I:C109. Additionally, IFNAR’s role in T-cell activation, specifically CD8+ 
T-cells, could be direct and cells may use IFN as a signal 3 cytokine. Many tools, 
including Ifnarfl/fl mice, can be used to study type I IFN signaling. By knocking out IFN 
102 
 
signaling in specific cell types, such as DCs, we can discover what scenarios type I IFN 
is required and better understand these signaling events.  
Perhaps, type I IFN has an indirect role in T-cell activation as well. Studies from 
the Kedl lab have shown that IL-27 production by cDC1s is required for CD8+ T-cell 
responses to subunit vaccination115,116. IL-27 is produced downstream from PRR 
engagement and type I IFN signaling114. IFN driven IL-27 production from cDC1s in 
response to DDO could be required for CD8+ T-cell responses in this system. 
Examination of IL-27 production by cDC1s in WT and Ifnar-/- mice would determine if IL-
27 is driven by DDO-induced IFN production. Additionally, mice lacking components of 
the IL-27 signaling pathway can be examined to confirm its role in responses to DDO-
adjuvanted vaccines.  
4.4.2 Lessons learned from PAMP adjuvants 
DDO are not alone as PAMP adjuvants. There are many experimental PAMP 
adjuvants being tested and the use of these adjuvants has vastly increased our 
knowledge of pathogen sensing that can be difficult to tease apart during infection 
settings. Experimental adjuvants poly I:C and cyclic dinucleotides have been heavily 
studied and provided new insight into early sensing of disparate pathogens.  
  Poly I:C was originally used to mimic viral dsRNA and its mechanism of action as 
an adjuvant is well characterized in mice. Poly I:C is sensed through both TLR3 and 
MDA569,216. Poly I:C was used to discover the cognate PAMP of TLR369. Injection of poly 
I:C results in a robust type I and type III IFN response109,217. In contrast, DDO does not 
result in the transcription of type III IFN upon s.c. injection. Poly I:C requires type I IFN 
for its adjuvancy, and type I IFN signaling is required for cross-presenting by cDC1s111. 
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Additionally, type I IFN signaling is required for Th1 and CD8+ T-cell responses to poly 
I:C-adjuvanted vaccines109,111. Poly I:C and its use as an adjuvant led to a great 
expansion in the understanding of innate responses to dsRNA, however, poly I:C is a 
synthetic PAMP. Poly I:C has laid an important foundation for PAMP studies but due to 
systemic IFN responses and resulting toxicity, is not suitable for prophylactic vaccination 
in humans99. Additionally, poly I:C is a heterogenous mix of synthetic dsRNA of varying 
lengths which further complicates its use in mechanistic studies.  
In addition to TLR agonists, other PAMPs are being explored as adjuvants. For 
example, cyclic dinucleotides (CDN) are currently being examined for use in vaccination. 
CDN, such as cGAMP, bind to the adaptor STING and lead to its activation. Additional 
CDNs, cyclic di-adenosine monophosphate (cyclic di-AMP) and cyclic di-guanosine 
monophosphate (cyclic di-GMP), have been tested as adjuvants in subunit vaccines215. 
CDNs induce humoral and cellular responses to both viral and bacterial pathogens. They 
induce CD8+ T-cell responses, but also induce a mixed Th1/Th17/Th2 memory 
response215. Interestingly, CDNs induce very different immune responses depending on 
the vaccination route. Intranasal delivery resulted in an immune response with type 1 
immunity characteristics however intramuscular delivery did not induce type 1 
immunity218. Studies investigating the mechanism of action of CDN adjuvants discovered 
that DCs require STING to generate adaptive immune responses219. However, the DC 
subtype responding to CDNs varies between vaccination routes215. These studies into 
the mechanism of adjuvancy of CDNs have demonstrated how widely immune 
responses can vary based on vaccination route and have been a useful tool to 
understand how these different environments favor different immune responses.  
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The use of PAMPs as adjuvants has greatly increased our knowledge of the 
intricacies of pathogen sensing. DDO is derived from a natural PAMP found during RNA 
virus infections. By studying how DDO is sensed and what cell types are involved in 
sensing, we gain deeper insight into not only how to induce type 1 immune responses 
during vaccination, but how viruses are recognized and the resulting immune response. 
4.5 Concluding Remarks 
Overall, this work provides insight into early responses to vaccine adjuvants that 
lead to type 1 immune responses to subunit and killed vaccines. These insights can be 
used to inform pathways to target during adjuvant development and improvement. This 
work uses a natural PAMP found during RNA virus infections to tease apart early 
sensing events out of the context of infection. DDO is not only a tool for understanding 
vaccine adjuvants, but for examining RNA sensing and downstream events. Discovering 
the mechanism of action of vaccine adjuvants is not just important for more tailored 
vaccine design, but also aids in understanding specific immune pathways required for 
efficient induction of adaptive immune responses. During infections many pathways are 
triggered simultaneously including viral sensing, cell death, as well as viral immune 
evasion. Therefore, it is difficult to tease apart the exact signals that lead to responses. 
Further characterization of adjuvants, simplified danger signals, inform the field of 
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